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General Introduction 
Medication non-adherence is an important public health concern, affecting health 
outcomes and overall health care costs. It is a widespread phenomenon and can be a 
barrier to safe and cost-effective use of medicines and services. The World Health 
Organization (WHO) define adherence as ‘‘…the extent to which a person’s behavior—
taking medication, following a diet, and/or executing lifestyle changes - corresponds 
with the agreed recommendations from a provider’’.  The failure to adherence to 
medication and physician prescriptions could lead to the individual not taking the 
prescribed drug, taking it at the wrong time or missing doses. Non-adherence can 
result in costly complications that are often more expensive than the medicines and 
worsen health outcomes. 
The first study on adherence was published in 1968. Later on, several papers have 
been published on this topic, with the aim to develop measures of adherence, to 
better understand factors related to poor adherence and to promote interventions to 
increase adherence. However, every effort to improve adherence was almost 
ineffective and non-adherence to medicines remains a challenge for health care 
professional and scientists. 
Non-adherence to treatment regimen is a prevalent problem of patients with chronic 
disorders. Adherence to long-term therapy for certain chronic illnesses in developed 
countries averages at only 50%. As the burden of chronic diseases continues to grow 
globally, so does the impact of non-adherence.  
The WHO estimates that the cost of non-adherence to drug therapy amounts to 125 
million euros per year in Europe including costs from avoidable hospitalizations, 
nursing home admissions, and premature deaths.  
High economic costs of poor adherence to the treatment derive from an increased 
demand for health care, as the clinical benefits remain unfulfilled. This involves higher 
hospitalization costs and greater recourse to additional resources of the Health 
Service. The expenditures’ impact is particularly important from a public health 
perspective, since an optimal allocation of limited available health resources is a key 
factor to maximize the population health level. Performing cost-effectiveness analysis 
by using real world data may be widely useful to support decision makers. Moreover, it 
would also be useful, from a third party payer, to evaluate the cost-effectiveness of 
increasing adherence. 
Adherence is becoming a priority included in the political agenda of health care system 
and in the European Commission (EC), adherence has been highlighted as a priority. In 
2012 was launched from EC the European Innovation Partnership on Active and 
Healthy Ageing (EIP-AHA) [http://ec.europa.eu/research/innovation-union/ 
index_en.cfm?section=active-healthy-ageing.]. The EIP-AHA A1 Action Group is 
focused on prescription and adherence. Part of the results of this thesis have been 
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made available to A1 Action Group as preliminary data that might be useful for the 
further focused interventions. 
 
Aim of this thesis 
This thesis aims to provide more evidence on relation between poor adherence and 
adverse outcomes and to define reason of poor adherence, by using drug-utilization 
approaches using different sources of health-related automated databases. The scope 
of the study is also to evaluate economic impact of enhancing adherence by using real-
life approach. The case study is population exposure to anti-osteoporotic drugs: with 
ageing populations, the burden of osteoporotic fractures on society will increase in the 
coming years and the prevention of osteoporotic fractures is therefore a major public 
health issue. 
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Chapter 1  
Medication Adherence 
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1.1 Medication Adherence 
During the last few decades, many different definitions of the process underlying the 
non-observance of physician’s recommendations have been employed. Adherence is a 
relatively recent term which has replaced the notion of compliance. In the past few 
years, the concept of adherence has gained popularity as it implies a more reciprocal 
and dynamic interaction between health care providers and patients, and it recognizes 
the influence of medication-taking behavior [1,2].  
Nowadays, the World Health Organization (WHO) definition of adherence has been 
universally accepted; ‘‘…the extent to which a person’s behavior—taking medication, 
following a diet, and/or executing lifestyle changes - corresponds with the agreed 
recommendations from a provider’’. This definition highlights the importance of an 
active involvement of the patient among with a good communication with the health 
professionals [3]. 
The first study on adherence was published in 1968 [4,5]. Later on, several papers have 
been published on this topic, with the aim to develop measures of adherence, to 
better understand factors related to poor adherence and to promote interventions to 
increase adherence. However, every effort to improve adherence was almost 
ineffective and non-adherence to medicines remains a challenge for health care 
professional and scientists. In developed countries non-adherence in the treatment of 
chronic diseases ranges from 30% to 50% and this rate is even higher in developing 
countries [6,7].   
This degree of non-adherence results in a high number of patients that do not get the 
maximum benefits of medical treatment; as a consequence they experience a poor 
quality of life, poor health outcomes and health care costs increase [8,9].  
Indeed, improvement of adherence may have a stronger effect on health outcomes 
than the development of new drugs [10]. Non-adherence to medical plans is a public 
health problem at every level of the population, but especially in older adults. Multiple 
chronic diseases and polypharmacy, the co-prescription of several drugs, are highly 
prevalent in older persons [11,12].  There is evidence that non-adherence increase 
with the number of chronic disease and the number of drugs. Chronic disease 
management requires a continuous psychological adaptation and behavioral 
reorganization that may lead to significant changes in respecting therapeutic 
indications [13].  
1.2 Economic impact of non adherence to medication 
Medication adherence is a growing concern to healthcare systems as nonadherence to 
pharmacotherapy has been associated with adverse  outcomes and higher costs of 
care. Adherence to therapy represents a key factors necessary to gain a significant 
6 
 
reduction in morbidity and mortality and to optimize the use of financial resources, but 
this aspect is  widely underestimated in clinical practice and by patients [14-18].  
The World Health Organization (WHO) estimates that the cost of nonadherence to 
drug therapy amounts to 125 million euros per year in Europe  including costs from 
avoidable hospitalizations, nursing home admissions, and premature deaths [3]. High  
economic costs of poor adherence to the treatment are caused from an increased 
demand for health care because the clinical benefits are unfulfilled. 
This involves higher hospitalization costs and greater recourse to additional resources 
of the Health Service.  
Several studies have suggested that patients with poor adherence to the treatment  
have higher costs for the health service than patients being more adherent to their 
treatment regimens. Furthermore, adherence to therapy is especially important for 
management of chronic diseases. In particular, a study by Sokol et al. related to four 
chronic conditions including diabetes, showed that a high level of adherence to 
therapy in diabetes is associated with lower costs related to illness and lower costs of 
hospitalization in patients more adherent to their treatment regimens [19].  
 
Figure 1 Adherence improbe health and reduces costs  
Interesting results are reported in a recent analysis conducted by IMS Institute for 
Health Care Informatics, which estimated the economic impact of the use of 
inappropriate drugs in 186 countries, including Italy. The study considered six chronic 
diseases of high social impact such as diabetes, osteoporosis, heart failure, HIV, 
hyperlipidemia, hypertension, estimating at approximately $ 300 billion cost of using 
non-optimal drug therapies. It shows that two thirds of these costs are attributable to 
approximately ten million avoidable hospitalizations, equivalent to about 140 billion 
dollars. In particular, the issue causing highest cost was nonadherence to therapy, with 
a value of almost 50% of the total. This cost would amount to about € 105 billion for 
the 69% and it is attributable to the hospitalizations [20]. 
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Adherence-based savings in medical costs appear to be driven primarily by reductions 
in hospitalization rates at higher levels of medication adherence.  Hospitalization is the 
largest component of medical costs, so it is likely that the changes in hospitalization 
risk are the primary driver of the cost savings observed at higher levels of adherence. 
1.3 Identifying poor adherence 
At present the most common model used to assess the causes of the low adherence is 
the Osterberg model.  This model evaluates  the negative effects on the patient’s 
ability to follow a medication regimen as a consequence of interactions among the 
patient, health care provider, and health care system (Fig.2) [14]. In this model, the 
level of adherence to pharmacological therapies is related to the type of relationship 
between the health care provider and the patient. 
 
Figure 2: Barriers to adherence:the interactions among the patient, 
health care provider, and health care system 
Variables related to how health care providers interact and communicate with their 
patients are key determinants of adherence and patient health outcomes [21-25]. The 
health care providers prescribe the medical regimen, interpret it, monitor clinical 
outcomes and provide feedback to patients [26]. Patients who view themselves as 
partners in the treatment process and who are actively engaged in the care process 
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have better adherence behaviour and health outcomes [27]. Warmth and empathy of 
the clinician emerge time and again as being central factors [28]. Whereas Physicians 
contribute to patients’ poor adherence by prescribing complex regimens, failing to 
explain the benefits and side effects of a medication adequately, not giving 
consideration to the patient’s lifestyle or the cost of the medications, and having poor 
therapeutic relationships with their patients [29-31]. Also, the health care delivery 
system has great potential to influence the adherence behaviour of patients. 
The policies and procedures of the health system itself control access to, and quality of 
care.  System variables include the availability and accessibility of services, support for 
education of patients, data collection and information management, provision of 
feedback to patients and health care providers, community supports available to 
patients, and the training provided to health service providers.  
More broadly, health care systems create barriers to adherence by limiting access to 
health care, using a restricted formulary, switching to a different formulary, and having 
prohibitively high costs for drugs, copayments, or both [32-34]. 
To improve the patient’s ability to follow a medication regimen, all potential barriers 
to adherence need to be considered. An expanded view that takes into account factors 
under the patient’s control as well as interactions between the patient and the health 
care provider and between the patient and the health care system will have the 
greatest effect on improving medication adherence. 
1.4 Determinants of patient adherence 
Adherence is not only affected by patient-provider relationship and/or systemic and 
organizational factors associated with health care system but also the nature of 
condition, complexity and duration of the treatment regimen, adverse drug reactions 
[35-37]. According to the WHO these determinants of non-adherence can be 
aggregated into five dimensions [3]: 
- social and economic,  
- health system related,  
- therapy-related,  
- condition-related   
- patient related 
In Table 1 lists all the factors relating to each dimensions [38]. 
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Table 1: Factors Reported to Affect Adherence 
1.SOCIAL AND ECONOMIC DIMENSION 
Limited English language proficiency 
Low health literacy 
Lack of family or social support network 
Unstable living conditions; homelessness 
Burdensome schedule 
Limited access to health care facilities 
Lack of health care insurance 
Inability or difficult accessing pharmacy 
Medication cost 
Cultural and lay beliefs about illness and treatment 
Elder abuse 
2. HEALTH CARE SYSTEM DIMENSION 
Provider-patient relationship 
Provider communication skills (contributing to lack of patient knowledge or understanding of the treatment regimen) 
Disparity between the health beliefs of the heath care provider and those of the patient 
Lack of positive reinforcement from the health care provider 
Weak capacity of the system to educate patients and provide follow-up 
Lack of knowledge on adherence and of effective interventions for improving it 
Patient information materials written at too high literacy level 
Restricted formularies; changing medications covered on formularies 
High drug costs, copayments, or both 
Poor access or missed appointments 
Long wait times 
Lack of continuity of care 
3.CONDITION-RELATED DIMENSION 
Chronic conditions 
Lack of symptoms 
Severity of symptoms 
Depression 
Psychotic disorders 
Mental retardation/developmental disability 
4.THERAPY-RELATED DIMENSION 
Complexity of medication regimen (number of daily doses; number of concurrent medications) 
Treatment requires mastery of certain techniques  
(injections, inhalers) 
Duration of therapy 
Frequent changes in medication regimen 
Lack of immediate benefit of therapy 
Medications with social stigma attached to use 
Actual or perceived unpleasant side effects 
Treatment interferes with lifestyle or requires significant behavioral changes 
5. PATIENT-RELATED DIMENSION 
Physical Factors 
Visual impairment 
Hearing impairment 
Cognitive impairment 
Impaired mobility or dexterity 
Swallowing problems 
Psychological/Behavioral Factors 
Knowledge about disease 
Perceived risk/susceptibility to disease 
Understanding reason medication is needed 
Expectations or attitudes toward treatment 
Perceived benefit of treatment 
Confidence in ability to follow treatment regimen 
Motivation 
Fear of possible adverse effects 
Fear of dependence 
Feeling stigmatized by the disease 
Frustration with health care providers 
Psychosocial stress, anxiety, anger 
Alcohol or substance abuse 
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1.5 Adherence to therapy: direct and indirect methods of measurement  
The methods available for measuring adherence can be broken down into direct and 
indirect methods of measurement.  
1.5.1 Direct methods  
Direct methods of measuring adherence include: 
- Measurement of concentrations of a drug or its metabolite in blood or urine 
and detection or measurement in blood of a biologic marker added to the drug 
formulation are examples of direct methods of measures of adherence. For 
instance, the serum concentration of antiepileptic drugs such as phenytoin or 
valproic acid will probably reflect adherence to regimens with these 
medications, and subtherapeutic levels will probably reflect poor adherence or 
suboptimal dose strengths.  
- Medication Event Monitoring System (MEMS) and electronic monitoring 
which consists of a monitoring system, applied to the packages delivered to the 
patient. Thus, each time the package is opened and the drug is extracted the 
system records the time and date. This method can be effective in identifying 
White Coat compliers or patients who lie in order to make a good impression to 
the doctor. This method is still considered the golden standard for the 
verification of the adherence to treatment in clinical trials. 
1.5.2 Indirect methods 
Indirect methods of measuring adherence include: 
- Self-reports to assess the knowledge of patient about the medications 
prescribed and the dosing schedule . This provide  information as to whether 
the patient is adherent with the actual dosing schedule. Subjective assessments 
by interviewers can bias adherence estimates. 
- Pill counts to be more precise counting the number of pills remaining in a 
patient's supply and calculating the number of pills that the patient has taken 
since filling the prescription is the easiest method for calculating patient 
medication adherence. 
- Pharmacy records based on pharmacy refills is one of the more frequently 
used methods in the literature and allows of obtaining refills and the frequency 
with which the refills are acquired reflect different aspects of a patient’s 
adherence behavior. This tool allows you to check the number and type of 
treatments  withdrawn from the patient and also any  interruptions occurring 
after the first prescription. 
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1.5.3  Advantages and disadvantages emerging form literature review 
The collaborative group of European Innovation Partnership A1 Action Group on Active 
and Healthy Ageing has reviewed the international literature on all possible indicators 
for medication adherence assessment: self-report, therapeutic drug monitoring, pill 
count, electronic monitoring devices, data reviews, prescription refill records, 
automated refill reminders, medication event monitoring systems, pharmacy claims 
data and prescription claims databases, electronic pharmacy databases. In Table 2 are 
presented the most commonly used tools focusing on their advantages and 
disadvantages, with information stemming from the literature review [39]. 
 
Table 2 Adherence assessment measures in the elderly: advantages and disadvantages emerging form 
literature review. 
Measure Advantages Disadvantages 
Self-report Easily understood by patients 
Uncomplicated to score 
Cost effective 
Allows to measure medication and 
behavioural adherence (no other 
method allows this) 
May focus on adherence, 
persistence, and discontinuation 
Useful screening tool in order to 
identify patients potentially at risk of 
non adherence in the future 
Allows discussion of reasons for 
nonadherence in clinical practice 
The evaluation may be performed 
also by interviewing the caregiver 
(proxy) thus obtaining significant and 
useful information for patient’s 
management 
Provides user-firendly information 
useful both for research purpouses 
and for every day clinical practice 
Questions may be standardized, but the test must 
be psychometrically sound 
May overestimate or understimate adherence 
(this can be reduced by performing the 
assessment as part of the clinical routine) 
Risk of false positive and lack of sensitivity to 
change due to memory recall issues 
(forgetfulness) and social desirability 
The validity of data collection may be affected by 
patient’s cognitive deficits 
Enables an overall description of medication non-
adherence only, compared to other methods that 
allows to differentiate between drugs in case of 
multiple pharmacy use 
Does not enable to differentiate among different 
diseases in a population (elderly) mainly 
characterized by plurimorbidity 
A self-report generic tool that assesses adherence 
in the elderly (crosswise diseases) considering 
both the complex medication regimen and 
behavioural suggestions is up to now not available 
in literature. 
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Measure Advantages Disadvantages 
Medication Event 
Monitoring System 
(MEMS) and 
electronic 
monitoring devices 
Allows analysis of dose-interval 
adherence and patterns of adherence 
over time 
Expensive 
Not feasible for most clinical settings 
Does not suit all pharmaceutical dosage forms 
May underestimate adherence 
Vulnerable to technologic malfunction 
Potential positive bias by reinforcing medication 
intake (Hawthorne effect) 
Patients may alterate data by collecting the drug 
from the device but not taking it (e.g. by throwing 
it away). 
High participant burden (e.g. multiple visits to 
download data, bulky caps, pillbox use 
problematic) 
No certainty that a dose that was removed was 
actually consumed or administered correctly 
(adherence taking and timing) 
Pill count Inexpensive 
An overall or global measure of 
medication adherence 
Time-consuming 
Inappropriate for most clinical settings 
Static measure, which does not reflect daily 
variability 
May overestimate adherence (if a patient is aware 
that a pill count is going to be conducted she/he 
may remove excess doses and discard them) 
Does not prove that medication has been 
swallowed 
Vulnerable to ‘‘pill dumping’’ 
Difficult to determine refill start date 
Assumes no medication stockpile or alternative 
supply 
No certainty that a dose that was removed was 
actually consumed or administered correctly 
(adherence taking and timing) 
Not suitable for medications taken on an as-
needed basis 
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Measure Advantages Disadvantages 
Pharmacy records 
based on pharmacy 
refills 
Data are easily obtained in ‘‘closed 
pharmacy systems’’ 
Allows for population-level analyses 
Immune to social desirability, recall 
bias, and tampering 
Drug-drug interactions and drug-drug 
duplication can be monitored 
A short time window will accurately 
include drugs for continuous use 
Feasible only in ‘‘closed pharmacy systems’’ 
Assumes that patients have a single source of 
medication (does not include free samples from 
physicians and pharmaceutical companies, or 
medications obtained through sharing with other 
family members or friends) and does not assess 
out of pocket medications 
Assumes that medication acquisition reflects 
adherence 
Studies do not always use standards method for 
operationalizing adherence (e.g., proprortion of 
days covered, medication possession ratio, 
medication gaps) 
Not useful if refills are mailed automatically or if 
several months’ supply is dispensed at one time 
Does not provide information upon timing 
(patients’ adherence to the prescribed timetable) 
Inadequate consideration of temporary nursing 
home care 
Does not include nonprescription medications 
lack of consensus terminology and algorithms 
among measures of the same concepts 
No certainty that a dispensed dose was actually 
consumed or administered correctly 
Therapeutic drug 
monitoring 
Prove the ingestion of medication  
Plasma concentration directly 
determines response 
May allow for detection or 
prevention of drug toxicity, which 
can lead to nonadherence 
May be advantageous for 
populations at risk for altered 
pharmacokinetics (e.g., patients with 
hepatic dysfunction, patients taking 
drugs that could interact) 
Expensive 
Invasive 
Only useful for a limited number of medications 
Need of a standardized method 
Levels of clinical indicators may be low for other 
reasons than nonadherence (e.g., diet, drug 
interactions) 
Interpretation of data depends on intra- and inter- 
individual medication metabolism variations 
Vulnerable to ‘‘white coat adherence’’ 
Only provides a snapshot of recent adherence 
Static measure 
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2.1 Automated Databases: definition and description 
In drug utilization studies information on prevalence, incidence, indication, duration of 
treatment and medication taking behavior can be derived from different sources. A 
considerable amount of data on drug usage is available as part of databases with 
administrative, commercial or clinical purposes.  
During the last decades the use of computerized databases containing medical care 
data has grown. These databases, called “automated databases”, are currently widely 
used as data sources for drug utilization studies. Administrative databases cover large 
sizes of population, and the data is readily available and easy to access.   
Requirements of an ideal database are that all parts are easily linked by means of a 
patient’s unique identifier, that the records are updated on a regular basis, and that 
the records are verifiable and are reliable.  
These source of data have been used in a substantial amount of published research [1-
3]. So called automated databases have existed and been used for drug-utilization and 
outcome research in USA since 1980, and are primarily administrative in origin, 
generated by the request for payments, or claims, for clinical services and therapies. In 
contrast, in Europe, medical record databases have been developed for use by 
researchers, and similar databases have been developed in the US more recently 
(Figure 1). The sources of drug utilization data vary from country to country depending 
on the level of sophistication of record keeping, data collection, analysis and reporting 
and the operational considerations of the health care system. The databases may be 
international, national or local in scope.  
 
Figure 1: Population Database 
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2.1.1  Administrative databases 
Administrative database arise from a person’s use of the health-care system. When a 
patient goes to a pharmacy and gets a drug dispensed or if a patient goes to a hospital 
or to a physician for medical care, information about type of service provided and the 
associated cost are registered for reimbursement by National Health 
System/insurance.  If there is a common patient identification number for both the 
pharmacy and the hospital discharge, these elements could be linked, and analyzed as 
a longitudinal medical record (Figure 2). 
 
Figure 2: Administrative Database 
Since drug identity and the amount of drug dispensed affect reimbursement, and 
because the filing of an incorrect claim about drugs dispensed is fraud, claims are often 
closely audited. Indeed, there have also been numerous validity checks on the drug 
data in claims files that showed that the drug data are of extremely high quality, that is 
confirming that the patient was dispensed exactly what the claim showed was 
dispensed, according to the pharmacy record. In fact, claims data of this type provide 
some of the best data on drug exposure in drug utilization research. 
Example of this kind of databases used for research aim are The Odense 
Pharmacoepidemiologic Database (OPED) in Sweden, the Tayside Medicines 
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Monitoring Unit (MEMO) in Scotland and the Kaiser Permanente Medical Care 
Program in California [4]. 
Italian administrative databases are usually used with a local scope, the Local Health 
Authorities are the owners of the data. Recently, many research initiatives have been 
put in place to carry out drug utilization studies on an interregional basis. 
2.1.2 Medical record databases  
Data from general practitioners (GPs) records of prescriptions can be more informative 
about the indication for drugs prescribed, diagnoses and other health-related data, 
although these records are not always consistently completed. 
Medical record databases are a more recent development, arising out of the increasing 
use of computerization in medical care. The best-known and most widely used medical 
record databases is the UK General Practice Research Database (GPRD) along with the 
newer database, The Health Improvement Network (THIN) [1]. As general practice 
databases, these contain primarily outpatient data. In Italy an example is the Health 
Search database. [5]. Medical record databases have the advantage to have a problem-
linked approach. When performing a drug-utilization study using these databases, 
there is no need to validate the data against the actual medical record, since one is 
analyzing the data from the actual medical record. However, there are also unique 
issues one needs to be concerned about, especially the uncertain completeness of the 
data from other physicians and sites of care. Any given practitioner provides only a 
piece of the care a patient receives, and inpatient and outpatient care are unlikely to 
be recorded in a common medical record (Figure 3). 
 
Figure 3: Medical Database: Structure and Functionally 
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2.1.3 Advantages  
Automated databases have several important advantages. First of all their potential for 
providing a very large sample size. In addition, these databases are relatively 
inexpensive to use, especially given the available sample size, as they are by-products 
of existing administrative systems. Studies using these data systems do not need to 
incur the considerable cost of data collection, other than for those subsets of the 
populations for whom medical records are abstracted and/or interviews are 
conducted. In addition, these databases can be population-based, they can include 
outpatient drugs and diseases, and there is no opportunity for recall and interviewer 
bias, as they do not rely on patient recall or interviewers to obtain their data. Another 
advantage is that these databases can potentially be linked to external other electronic 
databases (e.g., death records, maternal-child records, police accident records), to 
expand the capabilities and scope of research. This requires using common 
identification elements (e.g., name and date of birth) and standardized semantics to 
allow communication across databases. 
2.1.4 Limitations 
The major weakness of such data systems is the uncertain validity of diagnosis data. 
This is especially true for administrative databases, and for outpatient data [1]. For 
these databases, access to medical record data for validation purposes is usually 
needed. This issue is less problematic for medical record databases. The addition of 
hospital discharge data to these resources can assist in diagnosis validity, as well [6]. 
In addition, such databases lack information on clinical data (e.g. blood pressure) and 
there are no data on smoking, alcohol, date of menopause, etc., all of which can be of 
great importance to selected research questions (Table.1). 
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Table 1: Bias and confounding in pharmacoepidemiological studies 
Source of bias Source of bias 
Information bias (misclassification) Distortion of the estimate of the association between a risk factor (e.g. 
use of a drug) and the occurrence of an event, due to a systematic 
difference in the way information concerning the measured parameter 
is collected for the groups being compared. 
Information bias may be either non-differential or differential. Non-
differential misclassification may occur if there is the same probability 
of being misclassified for all study subjects and may lead to an 
underestimation of the hypothesized relationship between exposure 
and outcome. 
Differential misclassification may occur when the error rate or 
probability of being misclassified differs across groups of study subjects 
and may lead to wrong conclusions. 
Selection bias Distortion of the estimate of the association between a risk factor (e.g. 
use of a drug) and the occurrence of an event, resulting from the 
measurements made in a simple which is not representative of the 
population to which the results are to be extrapolated. Some examples 
include admission bias, diagnostic bias and survival bias. 
Confounding Systematic error resulting from the fact that a secondary variable is 
linked both to the exposure and the event of interest, which can wholly 
or partially explain their association found in an epidemiological study. 
2.1.5 Specific applications 
The principal aim of drug utilization research is to improve the rational use of drugs in 
real world setting, automated databases are used as data sources in the following 
research fields: 
 
• Description of drug use patterns (statistics on drugs) 
• Medication taking behavior (adherence to therapy) 
• Early signals of irrational use of drugs (pharmacovigilance) 
• Quality control of drug use (clinical audit) 
• Economic aspects of drug use (pharmacoeconomic) 
• Drug utilization studies and drug policy decisions.  
Given the frequent use of automated databases as data resources for drug utilization 
research in the recent past, much has already learned about their appropriate role. 
However, care must be taken to ensure that all potential confounding factors of 
interest are available in the system or addressed in some other way, that diagnoses 
under study are chosen carefully, and that medical records can be obtained when 
needed to validate the diagnoses [1]. 
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2.2 Drug utilization metrics:  the ATC/DDD methodology  
In 1996, World Health Organization (WHO) developed the ATC/DDD system from a 
European to an international standard in drug utilization studies. The main purpose of 
the ATC classification is as a tool for presenting drug utilization statistics and it is 
recommended by WHO for use in international comparisons. 
The Anatomical Therapeutic Chemical (ATC) classification system divides the drugs into 
different groups according to the organ on which they act and according to their 
chemical, pharmacological and therapeutic properties. Drugs are classified in 14 main 
groups at five different levels (Figure 4). The fifth level identifies the chemical 
substance (Figure 5).  
ATC I Level DESCRIPTION 
A ALIMENTARY TRACT AND METABOLISM 
B BLOOD AND BLOOD FORMING ORGANS 
C CARDIOVASCULAR SYSTEM 
D DERMATOLOGICALS 
G GENITO URINARY SYSTEM AND SEX HORMONES 
H 
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND 
INSULINES 
J ANTIINFECTIVES FOR SYSTEMIC USE 
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 
M MUSKOLO-SKELETAL SYSTEM 
N NERVOUS SYSTEM 
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 
R RESPIRATORY SYSTEM 
S SENSORY ORGANS 
V VARIOUS 
Figure 4: ATC main groups 
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ATC Level DESCRIPTION 
M 
MUSCULO-SKELETAL SYSTEM 
(1st level, anatomical main group) 
M05 
DRUGS FOR TREATMENT OF BONE DISEASE 
(2nd level, therapeutic subgroup) 
M05B 
DRUGS AFFESTING BONE STRUCTURE AND MINERALIZATION 
(3rd level, pharmacological subgroup) 
M05BA 
BISPHOSPHONATES 
(4th level, chemical subgroup) 
M05BA04 
ALENDRONIC ACIS 
(5th level, chemical substance) 
Figure 5: Structure of ATC code 
The Defined Daily Dose (DDD) is defined as ‘the assumed average maintenance dose 
per day for a drug used for its main indication in adults’. The DDD is a unit of 
measurement and does not necessarily correspond to the recommended or prescribed 
daily dose. The DDD is often a compromise based on a review of the available 
information about doses used in various countries. Drug utilization figures should 
ideally be presented as numbers of DDDs per 1000 inhabitants per day or, when drug 
use by inpatients is considered, as DDDs per 100 bed-days.  
Each chemical substance has to be connected to the appropriate ATC code and DDD. 
The ATC/DDD system is of paramount importance to drug utilization research in order 
to improve quality of drug use. The DDD is a stable drug utilization metric that enables 
comparisons of drug consumption between healthcare systems, regions and countries 
and therefore makes it possible to examine trends in drug use over time and in 
different contexts. The European WHO Collaborating Centre for Drug Statistics 
Methodology in Oslo, Norway, is responsible for coordinating the use of the ATC/DDD 
methodology (http://www.whocc.no) [7]. 
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2.3 Definition and measurement of exposure and outcome. 
Outcomes of interest in drug utilization studies can include diseases or conditions, 
medical procedures, laboratory tests results, or the use of particular medication, 
including medication adherence and persistence. 
The primary exposure of interest is usually the drug exposure. It must be noted 
however, that diseases, conditions or procedures may also be exposures of interest. 
The most frequently used and the most accurate measurement of drug exposure is 
outpatient prescription/pharmacy records [8,9].  
 
Figure 6: Waiting time distribution 
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2.4 Pharmacy records as tool to measure medication compliance and 
persistence. 
Pharmacy records or pharmacy claims data offer a useful tool for assessing medication 
taking behavior and are particularly useful for the evaluation of drugs intended for 
long term therapy. In recent years, pharmacy claims databases have been used 
successfully to describe adherence and persistence to medication in various chronic 
diseases [3,10,11]. Furthermore they have been used to assess the duration and 
dosage of drug therapy or treatment, treatment switching, clinical and socio-
demographic predictors of adherence and persistence to treatment, and the impact of 
medication taking behavior on clinical outcomes.  
Pharmacy refill or pharmacy claims databases contain details on dispensed drugs and 
therefore set an upper limit for actual drug assumption. The underlying premise of 
measuring medication taking behavior using pharmacy refill data is that if patients do 
not receive timely refills from the pharmacy, they are either missing doses or not 
taking their medication at all. There are many different ways of assessing medication 
taking behavior using pharmacy records. Medication taking behaviour can be defined 
in terms of two distinct variables; compliance which is acting in accordance with the 
prescribed interval and dosage of the treatment and persistence which is continuing 
the treatment for the prescribed duration of time (Figure7) [10].  
 
Figure 7: Definitions of compliance and persistence 
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2.4.1 Medication Compliance 
Medication compliance refers to the act of conforming to the recommendations made 
by the provider with respect to timing, dosage, and frequency of medication taking. 
Therefore medication compliance may be defined as “the extent to which a patient 
acts in accordance with the prescribed interval and dose of a dosing regimen” [10].  
Compliance can be calculated as both a continuous and dichotomous measure. As a 
continuous measure, the most common methods, as outlined and proposed by the 
International Society of Pharmacoeconomics and Putcomes Research (ISPOR) working 
group, are by way of Medication Possession Ratio (MPR) and Proportion of days 
covered (PDC) [11,12]. 
Medication Possession Ratio (MPR) is defined as the ratio of days under medication 
supplied to days in a time interval: 
 
MPR =  Number of days of medication supplied within the refill interval 
Number of days in refill interval 
 
 
Proportion of Days Covered (PDC)  is defined as the number of days covered over a 
time interval: 
 
PDC =   Number of days of medication covered 
Number of days in follow up period 
 
The numerator of the PDC is not merely a sum of the ‘days supplied’ by all 
prescriptions filled during the period. Rather, filled prescriptions are evaluated using a 
set of rules to avoid double-counting covered days. Thus, the PDC is always a value 
between 0 and 1.  
PDC differs from MPR in that it credits the patient with finishing the current fill of 
medication before starting the next refill. Some believe compliance can be 
overestimated by simply summing the days supply because patients usually refill their 
medication before completing the current fill. 
The main limit of these methodologies is that multiple periods of non-exposure in the 
short term can result in the same MPR/PDC as few periods of non-exposure in the long 
term and duration of treatment needs to be considered [11]. 
These measures are often dichotomized and patients with a PDC or MPR≥ 80% are 
generally classified as adherent to their treatment (< 80% non-adherent). However 
unless an appropriate threshold can be justified these measures should be analyzed as 
continuous variables. [13] 
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Figure 8: Compliance measure by proportion of days covered 
2.4.2 Persistence 
Medication persistence may be defined as “the duration of time from initiation to 
discontinuation of therapy” [10]. This is usually the time, measured in days, from first 
claim to last claim (plus the days supply of the last claim) considering the days between 
refills [14]. Continuing to take any amount of the medication is consistent with the 
definition of persistence. This definition can be operationalized in both prospective 
and retrospective assessments by determining the initiation of treatment, or a point in 
time during chronic treatment, to a point in time defined as the end of the observation 
period. Persistence analyses must include a prespecified limit on the number of days 
allowed between refills, considered the “permissible gap”.  
Methods for gap determination should be based on the pharmacologic properties of 
the drug and the treatment situation (Figure 9). By definition, persistence is reported 
as a continuos variable in terms of number of days for which therapy was available. 
Persistence may also be reported as a dichotomous variable measured at the end of a 
predefined time period, considering patients as being “persistent” or “nonpersistent”.  
The most relevant issue about this methodology is that periods of non-exposure that 
are shorter than the gap are not taken in account. This limitation derives from the fact 
that in pharmacy databases it is very difficult to estimate exactly the effective daily 
dose taken by the patient. In order to overcome this issue it is necessary to adjust the 
persistence analysis model to take into account information about the 
pharmacological characteristics of the drug being studied as well as the specific 
objectives of the study [10].  
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Figure 9: Methods for gap determination 
2.4.3 Benefits 
The benefits of using pharmacy refill records is that they are potentially immune from 
social desirability, recall bias and tampering and have ease of reproducibility in other 
settings. They represent an important tool for the indirect measurement of the levels 
of adherence and persistence to treatment and are easily accessible, low-cost, 
constantly updated, and permit a comprehensive evaluation of the entire population. 
They also provide an effective means of helping physicians to identify both patients 
with low adherence and persistence and those with a higher probability of becoming 
poorly adherent or interrupting or stopping therapy [15]. Other indirect measures of 
medication taking behavior such as patient interviews, pill counts, and clinician 
assessments are not practical to perform on large populations. [13] 
2.4.4 Disadvantage 
The major disadvantage of using pharmacy refill records is their inability to determine 
if the patient actually consumed the dispensed medication. The refill data must also be 
complete (a closed system) with patients unlikely to obtain medications from other 
sources not captured by the database. Measures of medication taking behavior are 
invalid if patients are obtaining medication in alternative ways such as free samples 
from physicians and pharmaceutical companies, or medications obtained through 
sharing with other family members [13]. Furthermore pharmacy refill or claims date 
does not measure out of pocket medications and may not account for treatment gaps 
due to hospitalization or nursing home stays.  
A number of different measures and definitions of adherence and persistence have 
been reported in studies conducted using pharmacy databases and this makes 
comparison of results between studies difficult. It is also difficult to measure 
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medication taking behavior where mail-order is used or several months supply are 
dispensed at once. Patients may retain large supplies of unused medications in their 
homes.  
Despite their limitations, the use of pharmacy refill records provides an important valid 
and relatively efficient method of assessing adherence and persistence in large 
population based research and likely to reflect medication taking behavior in the real 
world setting.   
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Chapter 3 
Economic evaluation in health care  
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3.1 Why is important economic evaluation in health care? 
Economic considerations have gained an increasingly prominent role in the planning, 
management and evaluation of healthcare systems, ranging from the design 
mechanisms for the reimbursement of healthcare providers and the definition of 
arrangements aimed at improving the access to care for households, to the definition 
of essential packages for insurance, as well as the provision of adequate information to 
inform decisions on whether or not to include new medicines on hospital, state or 
National formularies [1-3]. Such an increased attention to the issues concerning cost 
and efficiency is motivated by the pervasive scarcity of resources relative to health 
needs and demand, driven by factors such as the HIV pandemic, the ageing of 
populations, the development of innovative but often expensive technologies and also 
by the heightened knowledge and expectations of healthcare consumers. All these 
forces, acting both on the demand and supply sides, have given rise to the need for 
sophisticated methods of quantitative analysis, including modelling of disease history 
and outcomes, econometric modelling for population-based resource allocation 
simulations, macro-level modelling of the impact of (ill-) health on wealth (and 
viceversa), and multi-state decision analytic models that assess the technical efficiency 
of health interventions [4-6]. 
3.2 Methods of economic evaluation 
The first aim of an economic evaluation is to “identify, measure, value and compare 
the costs and consequences of alternatives being considered” to inform “value for 
money” judgments about interventions or programmes. Usually, consequences of an 
investment in health technologies are measured as health outcomes of the 
alternatives being compared, although there may be other types of consequences, 
such as those relating to process, considerations on social consequences of a new 
treatment, effects of a specific technology on the level of treatment compliance.  
 
The four main types of full economic evaluation all approach costs in the same way,  
but differ in the way they approach outcomes [7]: 
- Cost-minimization analysis is used where the consequences of two or more 
interventions are broadly equivalent, and so the analysis of differences between 
them is limited to a cost comparison. This approach is only meaningful for 
protocols with the same effectiveness or side effects, and is hardly applicable to 
heterogeneous classes of drugs like the osteoporosis drugs. 
- Cost-benefit analysis measures both costs and benefits in monetary terms. This 
approach aims to demonstrate that a program will yield a net welfare gain, and 
ranks interventions according to the net benefit they provide. The practical 
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difficulties of measurement and valuing health benefits have limited the use of 
this type analysis in healthcare. 
- Cost-effectiveness analysis (CEA) compares costs and outcomes espressed in a 
single dimension, such as a fracture avoided, BMD gained, or life-years gained. In 
addition, it is not possible to compare the cost-effectiveness across disease areas 
for example, to campare the cost-effectiveness of a statin in cardiovascular 
disease with a bisphosphonate in osteoporosis. 
- Cost-utility analysis (CUA) compares costs and otcomes espressed in Quality 
Adjusted Life Years (QALYs). As noted above, the QALY integrates the benefits in 
terms of reduction in mortality and morbidity [ref]. In addition, this approach 
allows comparison across different health programs and diseases by using a 
generic unit of measure. For this reason, cost-utility is the most widely applied 
type of economic assessment.  
There are different categories of costs that may or may not be included in an economic 
evaluation. It is essential to specify and justify the perspective under which the analysis 
is undertaken. The most common perspectives used are those of healthcare payers 
and society. The social perspective is the broadest, including direct and indirect 
medical costs, and is theoretically preferred. However, most local health care agencies 
recommend the use of a healthcare payer perspective in order to take into accont only 
those cost items falling on the third party payor’s budget. 
Cost-effectiveness analysis and cost-utility analysis are much more common than cost-
benefit analysis when assessing the value for money of a new technology. Both these 
analyses are based on the concepts of incremental costs and incremental benefits of 
the new technology compared to the standard of care or any other alternative 
treatment. Hence, the output of cost-effectiveness and cost-utility analysis is an 
estimate of the cost per unit of effectiveness gained and of the cost per QALY gained, 
respectively. Such a measure, referred to as Incremental Cost-Effectiveness Ratio 
(ICER), is then compared to a certain acceptability threshold that is an estimate of the 
cost/effectiveness unity above which the technology under study cannot be funded. 
Such a measure can be interpreted as a proxy of the efficiency of a specific healthcare 
system in producing health, since it represents the cost beard to produce an additional 
unity of health, however that may be measured.  
Obviously, in this context a central role is played by the concepts of “opportunity cost” 
and “incremental change” especially in publicly funded health care systems. As a 
matter of fact, in such situations limited resources are available to the decision maker 
who is responsible for allocating them among alternative uses. Choices must be made 
among effective health care interventions, and the decision to fund one means that 
others cannot be funded. The opportunity cost of funding the chosen intervention can 
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be seen as the health benefits that could have been derived from funding the next best 
alternative [8]. 
Threshold analysis is possible whenever a certain cost/unity of effectiveness 
representing the maximum willingness to pay of the system is available. So far, 
acceptability thresholds have been derived from past decisions of the national health 
authorities considering the cost/QALY gained of the services and good provided and 
reimbursed but national health services in several countries. However, the QALY is the 
only outcome measure for which some estimation of the acceptability threshold exists. 
Conversely, when the analysis is performed adopting another measure of health 
benefits, threshold analysis is still possible but the analysts has to hypothesize a 
threshold value based on other considerations, such as epidemiologic aspects, explicit 
estimations of the willingness to pay and so on. 
Every time an intervention with an ICER equal to the acceptability threshold is included 
in the agenda of the public decision maker a QALY is forgone in some other clinical 
area, whereas when a treatment with an ICER lower than the threshold is introduced 
in clinical practice by a public decision maker, this decision frees up resources for 
further investments, improving the overall efficiency of the system.  
However, often the cost-effectiveness is not the sole criterion for decisions concerning 
the allocation of healthcare resources. As a matter of fact, consideration on equity and 
distributive justice as well as the high innovative content of the new technology or the 
relevant burden of disease can justify the introduction of technologies characterized 
by high incremental cost effectiveness ratio. As a result, these decisions imply the loss 
of more than one QALY in other clinical areas and decrease the overall efficiency of the 
system in producing health.  
The possibility of analyzing the decision problem under a wide perspective has 
certainly been contributing to the widespread use of cost-utility analysis as well as the 
increasing utilization of QALYs as a measure of health outcomes. 
For these reasons, the ICER (Incremental cost effectiveness ratio), is currently the most 
commonly used cost-effectiveness indicator.  
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3.2.1 Cost-effectiveness plane 
When a cost-effectiveness analysis is performed, treatments under study can be 
graphically represented on a cost-effectiveness plan where incremental costs are 
reported on the y-axis and incremental benefits are reported on x-axis. Each treatment 
is represented by a point on the CE plane whose coordinates are the incremental 
effectiveness and incremental costs with respect to the comparator, with ICER being 
represented by the slope of the segment joining that point with the origin of axes. An 
example is reported in Figure 1. 
 
Figure 1. Example of cost-effectiveness plan. 
If a treatment falls in the second quadrant it is more effective and less expensive than 
the comparator. Thus, it is characterized by a negative ICER, being the numerator (i.e. 
incremental cost) smaller than zero. In this case, if cost-effectiveness was the unique 
decision criterion, the new treatment should be immediately accepted without any 
further investigation. 
The opposite situation happens when the treatment falls in the fourth quadrant. Once 
again, the ICER is negative but, in this case, the denominator (i.e. incremental 
effectiveness) is negative, while the numerator (i.e. incremental cost is still positive). A 
technology with this features is dominated by the comparator (i.e. the system could 
save money and improve health by implementing the alternative regimen), and should 
be immediately rejected.  
Positive ICERs occur both in the first and in the third quadrant. In particular, in the 
third quadrant the new treatment is less effective and less expensive than the 
comparator (both numerator and denominator of the ratio are negative), whereas in 
the first quadrant the new treatment is more effective but also more expensive than 
the alternative regimen (both the numerator and the denominator of the ratio are 
positive). The treatment falling in the third quadrant should not be taken into account 
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for equity reasons, while treatments falling in the first quadrant require a threshold 
analysis in order to appraise the cost-effectiveness.  
3.2.2 Limitations 
The ICER approach is very intuitive and this simplicity probably justifies its widespread 
use. However, it exhibits some limitations that deserve mention.  
A first problem arises with the interpretation of negative results. Indeed, if a negative 
cost per QALY is reported, without any specification of how that ratio was obtained 
(i.e. which incremental values were included in the ratio) it is not possible to 
understand if the treatment is dominant or dominated. Similar difficulties concern the 
interpretation of ICERs which have the same scale but fall in opposite quadrants of the 
cost effectiveness plane. An example is depicted in Figure 2.  
 
Figure 2. Difficulties in the interpretation of ICERs. 
Treatments A and B in Figure 4 both report an ICER of 200£/QALY. However, treatment 
A produces a gain of 0.5 QALY against an incremental cost of 100£, thus its ICER should 
be compared to a certain cost-effectiveness acceptability threshold. Conversely, 
treatment B yields a saving of £100, but implies the loss of 5 QALY. Despite its ICER has 
same scale of that of treatment A, this treatment should not be considered. Therefore, 
also positive ICERs, if not correctly specified, can be misleading. 
3.2.3 From ICER to Net Benefit 
The net benefit approach consists in rearranging the formula of the ICER so that the 
increment in the effect is multiplied by the threshold: 
NB = λ*ΔE – ΔC, 
where λ is the considered cost-effectiveness threshold. The decision rule within the 
ICER framework is “if: 
ΔC/ ΔE< λ, 
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then the new treatment should be accepted”. Within the net benefit approach the 
decision rule becomes: “if:  
λ*ΔE – ΔC > 0, 
then the new treatment should be accepted”. 
 
Using the net benefit approach simplifies the interpretation of results: dominated 
strategies have a negative NB. Dominant strategies have the highest NB. Whenever a 
strategy has a positive NB it is suitable to be chosen. However, if there are many 
options the one with the highest NB should be selected [7]. Plotting the net benefit of 
a strategy against threshold values we can visualize the ICER of the technology which is 
represented by the point in which the NB line crosses the x-axes 
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4.1 Osteoporosis drugs in real world clinical practice : an analysis of 
Persistence  
Abstract 
The aim of our retrospective cohort study is to analyze the persistence rates in relation 
to antiosteoporotic drugs by using administrative databases in the Campania Region. 
Patients, aged ≥ 40 years, were included if at least one prescription for any 
antiosteoporotic drugs had been filled in between January 1, 2009 and December 31, 
2009. Overall, 37,594 patients were incident users of antiosteoporotic drugs. 
Among them, 15,978 patients had undergone spot-therapies. A total of 2,618 (14.1%) 
were classified as switchers. Switching rates were highest for patients taking 
Alendronate 18.9 or Strontium Ranelate 15.0 and lower for patients taking 
Ibandronate 12.8 or Risedronate 10.8. In the overall population 33.5% of subjects were 
still on therapy after 6 months. At one year, persistence rates were: Ibandronate 
21.6%, Risedronate 15.8%, Alendronate + Vitamin D 15.7%, Raloxifene 14.3%, 
Alendronate 12.6% and Strontium Ranelate 5.0%. 
4.1.1 Introduction 
Osteoporosis represents a huge threat to global health and national healthcare 
systems (1). Its treatment involves several therapeutic tools, including drugs (2) and  
long-term drug therapy is generally considered for chronic disorders such as 
osteoporosis. Patients with chronic disorders are more likely to be non adherent 
and/or non-persistent to treatment than those with other diseases. Adherence is 
currently defined as the extent to which patients take medication as prescribed by 
their physicians whereas persistence is the time from therapy initiation to 
discontinuation (3). Numerous studies have shown that inadequate persistence to 
prescribed therapies induces an increase in both morbidity and mortality. Lack of 
persistence is common among patients using oral osteoporosis treatments despite the 
availability of safe and efficacious therapies (4), and causes the  mitigation of the 
therapeutic benefit and increase risk of fracture (5). Only women with higher 
persistence (>66%) had a larger increase in spine and hip BMD (6). A large survey of 
Italian osteoporotic women reported that the most common reasons for lack of 
persistence are: appearance of side effects, costs, inconvenient dosing, advice from 
other specialists, cultural and economic conditions, lack of motivation. Furthermore, 
the survey demonstrated that the treatment discontinuation rate varies considerably 
with the type of treatment (7). 
Compared to epidemiological surveys, the use of administrative databases represents 
a significant step forward, providing a useful tool for indirect measurement of the 
levels of persistence (8). Administrative databases are also easily accessible and 
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constantly updated allowing the entire population to be evaluated. In this paper, we 
propose a retrospective cohort study in order to analyze the persistence to 
antiosteoporotic drugs in the Campania Region by using such data. 
4.1.2 Materials and Methods 
Data source 
Data were retrieved from an administrative database of pharmacies - derived regional 
data regarding medication prescriptions in Campania region, Southern Italy, which has 
a population of about five million inhabitants. For this study, we used data collected in 
the years 2008-2010. The database contains all the information ( i.e. drug code, dose, 
formulation, number of packages, date of prescription, date of dispensation) 
concerning outpatient drug prescriptions reimbursed by the National Health Service 
(NHS) and dispensed in pharmacies in the region. The database also includes 
demographic information (i.e. age, gender). To protect the patients’ privacy, the 
patient code was encrypted into a unique  alpha-numeric code. The reliability of this 
strategy as a way of producing epidemiological information has been previously 
documented (9). The drugs are classified according to the Anatomical Therapeutic 
Chemical (ATC) classification system. 
Study cohort 
The study was designed as a retrospective cohort study. A patient selection flowchart 
is shown in Figure 1. Patients 40 years of age or older were included if at least one 
prescription for any antiosteoporotic drugs [Alendronate (ATCV:M05BA04); 
Alendronate + Vitamin D (ATC V M05BB03); Risedronate (ATC V M05BA07); 
Ibandronate (ATC V M05BA06); Raloxifene (ATC V G03XC01); Strontium Ranelate (ATC 
V M05BX03)] had been filled in between January 1, 2009 and December 31, 2009. The 
date of first prescription was considered as the index date. 
Five patient categories were excluded: (i) patients who had been prescribed at least 
one antiosteoporotic drug within 365 days prior the index date (to ensure that the 
selected patients are incident users) ; (ii) patients who had been prescribed 
antineoplastic drugs (L01) during follow-up; (iii) patients who had not had reach at 
least one year of follow-up; (iv) patients who received only one prescription of 
antiosteoporotic drug during the follow-up; (v) patients who received a co-prescription 
of two different antiosteoporotic drugs on the index date. 
Patients were followed from the index date until the discontinuation of 
antiosteoporotic therapy or until the end of the observation period (31 December 
2010). For each patient, the following characteristics were assessed from the database 
at baseline: age, gender, co-prescription of calcium/ Vitamin D. Patients were stratified 
into six cohorts based on the antiosteoporotic drug prescribed (ATC V) on index date. 
On the basis of the first antiosteoporotic drug prescribed, patients were further 
classified into: (i) patients continuing the first-line drug for at least 365 days 
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(continuers); (ii) patients changing from the first-line to another drug (switchers); (iii) 
patients interrupting the first-line drug during follow up (discontinuers). 
Persistence 
Persistence was defined as the length of time (in days) from the date of the index 
prescription to the date of discontinuation therapy. Discontinuation was evaluated by 
using the gap method. A gap is a period during which no medication is available to the 
patient. A treatment period was considered discontinued if the gap between two 
prescriptions exceeded a period covered by drug prescribed > 30 days. Persistence was 
analyzed according to the type of antiosteoporotic drug. To avoid underestimating true 
persistence, switching of medications was allowed when establishing persistence 
status for all treatments combined. Switchers were considered discontinuers at the 
date of switch when persistence was estimated for the individual treatment types. 
Statistical Analysis 
Baseline characteristics of the study population were analyzed using descriptive 
statistics. Persistence estimates were derived using non-parametric survival analysis. 
Kaplan–Meier survival functions were estimated with treatment discontinuation as 
failure event. Discontinuation rates were assessed at 180 and 365 days. All analyses 
were performed using SPSS software version 17.1 for Windows ( SPSS Inc, Chicago, IL, 
USA) 
4.1.3 Results 
Cohort characteristics 
A total of 86,942 patients received a prescription for an antiosteoporotic drug between 
January 1 2009 to December 31 2009. Distribution of exclusion criteria is shown in 
Figure 1.  
Overall, 37,594 patients were incident users of antiosteoporotic drugs. Among them, 
15,978 patients had only one prescription of antiosteoporotic drug (spot therapies) . 
The final cohort consisted of a total of 18,515 incident users of antiosteoporotic drugs: 
1,406 (7.8%) males and 17,109 (92.2%) females. The mean age [SD] of the cohort was 
68.9 [10.1] years [(68.7 [10.1] females) (71.1 [10.4] males)]. 
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Figure 1: Patient selection flowchart 
 
Baseline characteristics of the study population are shown in Table 1. Alendronate, 
alone and in association with Vitamin D (36.7%), was the most commonly prescribed 
drug, followed by Strontium ranelate (30.1%) Risedronate (23.6%), Ibandronate (8.5%) 
and Raloxifene ( 0.6%). Co-prescription with calcium and Vitamin D was most common 
for Risedronate, bimonthly, and Ibandronate (56.4%, 52.5%), respectively. On the 
other hand, patients starting with Strontium Ranelate were given fewer co-
prescriptions of calcium and Vitamin D (40.4%). In the overall study cohort, 
2,618(14.1%) were switchers. Switching rates were highest for patients taking 
Alendronate 437 (18.9) or Strontium Ranelate 838(15.0) and lower for patients taking 
Ibandronate 202 (12.8) or Risedronate 475(10.8) (Table 1). 
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Table 1 Baseline characteristics of the study cohort 
 Alendronate 
N(%) 
2,317 (12.5) 
Alendronate + 
Vit D 
N(%) 
4,501 (24.2) 
Ibandronate 
N(%) 
1,581 (8.5) 
Raloxifene 
N(%) 
112 (0.6) 
Strontium 
Ranelate 
N(%) 
5,605 (30.1) 
Risedronate 
N(%) 
4,399 (23.6) 
Total 
N(%) 
18,515 
P value 
Sex (F) 2,093 (90.3) 4,147 (92,1) 1,491 (94.3) 111 (99.1) 5,253 (93.7) 4,014 (91.2) 17,160 
(92.2) 
< 
0.0001 
Age 
(mean+SD) 
68.6 ± 10.2 69.0 ± 10.1 68.6 ± 9.9 63.8 ± 10.5 69.5 ± 10.0 68.4 ± 10.2 68.9 + <0.0001 10.1 
Switch  
 437 (18.9) 643 (14.3) 202 (12.8) 23 (20,5) 838 (15.0) 475 (10.8) 2,618 (14.1) < 
0.0001 
Co-prescription Calcium and Vitamin D  
 1,123 (48.5) 853 (18.9) 830 (52.5) 35 (31.3) 2,265 (40.4) 2,479 (56.4)   7,585 
(41.0) 
< 
0.0001 
Probability of discontinuation 
In the overall cohort study, persistence rates were evaluated at 180 and 365 days after 
initiation of treatment. In the overall population, 33.5% of subjects were still on 
therapy after 6 months. At one year, persistent patients were 13.9%. On the other 
hand, Kaplan-Meier analysis showed the details grouped by individual drugs (Figure 2). 
At 12 months the number of patients that remained on treatment were: Ibandronate 
21.6%, Risedronate 15.8%, Alendronate + Vitamin D 15.7%, Raloxifene 14.3%, 
Alendronate 12.6% and Strontium Ranelate 5.0%. 
 
 
Figure 2: 12 months’ persistence (%) of antiosteoporotic drugs 
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4.1.4 Discussion 
Anti-osteoporotic drugs have fully demonstrated their efficacy in several randomized 
controlled trials. In clinical practice, however, anti-fracture efficacy is significantly 
reduced by the lack of compliance and persistence in the treatment. Medication 
compliance (synonym: adherence) refers to the degree or extent of conformity to the 
recommendations as regards day-to-day treatment by the provider with respect to the 
timing, dosage, and frequency. Persistence, on the other hand,  is defined as the 
duration of time from initiation to discontinuation of therapy (3). In a large, 
commercially insured population, suboptimal adherence with bisphosphonate (BP) 
treatment was associated with increased fracture risk (4). Gallagher et al, in a study 
based on the data from the General Practice Research Database, showed that although 
use of bisphosphonates was associated with fracture risk reduction after 12 months of 
treatment, only 58% of the patients were treated for at least 1 year (10). In a 
population study Huybrechts et al. confirmed that a large proportion of patients stop 
treatment before a meaningful threshold (6 - 12 months) and/or have an intermittent 
pattern of drug use, resulting in low adherence that is associated with a 17% increase 
in the fracture rate, a 37% increase in the risk of all-cause hospitalization; and higher 
average monthly costs for all medical services combined (11). In patients with hip 
fractures too, the twelve-month mean medication possession ratio was 67%, while the 
rate of persistence was 41% (12). Siris et al. confirmed in a systematic review that low 
compliance and persistence rates for osteoporosis therapies in the real-life setting 
result in increased rates of fragility fractures (13). A recent systematic review focused 
on adherence to bisphosphonates showed a 46% increased fracture risk in non-
compliant patients versus compliant patients(5). Our data showed that the persistence 
to therapy is significantly worse than reported in literature. Indeed we found that 70% 
of the entire sample had discontinued the treatment six months after initiation of 
therapy. At one year, only 13.9% of the subjects were still on treatment. The most 
important determinant of both persistence and compliance to treatment is the type of 
drug and the dose regimen. Kothawala P. et al conducted a systematic review and 
meta-analysis of real-world adherence to drug therapy for osteoporosis and found that 
adherence is enhanced with weekly dosing compared with daily dosing (14). An 
International Osteoporosis Foundation survey found that women considered most of 
the disadvantages of oral BP therapy to be related to inconvenient dosing regimens 
and concerns about possible adverse events, in particular those at the gastrointestinal 
level, which are minimized by complex administration procedures (15). A change in 
dosing frequency would have a positive effect upon adherence to therapy. In our 
cohort we found a significant difference in persistence according to whether drugs 
were drugs administered daily, weekly or monthly. The worst persistence with 
treatment was found in patients treated with strontium ranelate - 5% in one year. The 
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best persistence rate found at one year has been found for Ibandronate (21.6%) which 
has a  monthly regimen. This result is considerably lower than that reported in 
literature and far below the threshold of clinical efficacy of an antiosteoporotic drug. 
The ability to proactively identify patients who are likely to become non-adherent may 
offer significant advantages for personalizing prescribing choices and adherence-
related interventions. In our study patients changing from the first-line to another drug 
(switchers) were 14.1%. Switching rates were highest for patients taking Alendronate 
18.9 or Strontium Ranelate 15.0 and lower for patients taking Ibandronate 12.8 or 
Risedronate 10.8. The high frequency of switch therapy in patients treated with 
ranelate may be due to its daily administration, while the low persistence with 
alendronate may be due to gastrointestinal side effects. An improvement action of 
osteoporosis management should include the employment of drugs with less frequent 
dosing, thus obtaining both an increase in rate of persistence and a reduction in  side-
effect. Recently, particular interest has been focused on the use of administrative 
databases as a tool for indirect measurement of the levels of persistence. Baio et al. (8) 
suggest the use of drug administrative databases to monitor adherence to 
osteoporosis treatment. They also propose a multifaceted approach, which includes 
the Triad Model (suggested by the World Health Organization) which involves patients, 
physicians and healthcare administrations. The integration of these strategies may 
have a widespread and economically sustainable impact on low adherence, and could 
improve treatment effectiveness and clinical outcomes in a real-life scenario. The 
limitations of our study are mainly related to the use of administrative databases as 
data source. Indeed, although these databases allow the inclusion of a large number of 
patients in real world conditions, they do not include important clinical findings that 
could influence persistence. 
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4.2 Rates and reasons for lack of persistence with anti-osteoporotic 
drugs: analysis of the Campania region database  
Abstract  
Subjects with chronic diseases are more likely to be non-persistent to pharmacological 
treatment. Lack of persistence is common among subjects using oral anti-osteoporotic 
drugs, and leads to increased risk of fragility fracture. The aim of our retrospective 
study is to analyze the rates and reasons for discontinuation of anti-osteoporotic drugs 
in the Campania Region. Subjects aged over 40 years were included if they had 
received at least one prescription for any anti-osteoporotic drugs. Data were obtained 
from an administrative database of regional data on outpatient drug prescriptions 
reimbursed by the National Health Service. Patients were followed until the 
discontinuation of anti-osteoporotic therapy or until the end of the observation 
period. A total of 30,048 were incident users of anti-osteoporotic drugs: 28,317 
(94.2%) females. The mean age of the cohort was 69.0±10.0 years. Weekly 
bisphosphonates (51.1%) were the most commonly prescribed drugs. In the overall 
population, persistence rates were 34.8% after 6 months and 13.4% at one year. A 
multivariate Cox proportional hazard analysis showed that daily regimen (HR 1.9) 
treatments remained at higher risk of early discontinuation compared to weekly 
regimen therapies. Our data showed that the persistence to osteoporosis therapy is 
significantly worse than reported in literature. 
4.2.1 Introduction 
Osteoporosis is a disease characterized by low bone mass and microarchitectural 
deterioration of bone tissue, leading to enhanced bone fragility and a consequent 
increased risk of minimal trauma fractures [1]. Fragility fractures are underestimated 
and this is often due to the underdiagnosis of osteoporosis in patients at higher risk, 
resulting in the undertreatment of this condition and consequently in an additional risk 
of fractures [2]. Osteoporosis treatment involves several therapeutic options, including 
long-term drug therapy [3]. Osteoporotic patients, like those suffering from other 
chronic disorders, are more likely to be non-adherent and/or non-persistent to 
pharmacological treatment. In 2008, the International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) Medication Compliance and Persistence Work Group 
defined compliance or adherence as “the extent to which patients take medication as 
prescribed by their physicians”, whereas persistence is the time from treatment 
initiation to discontinuation [4]. It was demonstrated that in osteoporotic patients, 
only women with higher persistence (>66%) had a larger increase in bone mineral 
density (BMD) at lumbar spine and hip [5], while low compliance and low persistence 
rates for anti-osteoporotic drugs lead to increased rates of fragility fractures [6]. A 
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systematic review showed a 46% increase of fracture risk in noncompliant patients to 
bisphosphonates treatment [7]. Our previous data showed that persistence to anti-
osteoporotic drugs is significantly worse in Southern Italy population than the one 
reported in world literature, with the 70% of the subjects that discontinued their 
treatment 6 months after the initiation, and only the 13.9% of them are still on 
treatment at 1 year [8]. The most common reasons for discontinuation from anti-
osteoporotic medication had been identified as side effects, costs, inconvenient 
dosing, advice from other specialists, socioeconomic conditions, and lack of motivation 
[9]. 
The aim of our study is to analyze, in a large population of Campania region, the rates 
and the risk factors for discontinuation of anti-osteoporotic drugs.  
4.2.2 Materials and methods 
Data sources and patient selection  
Data were retrieved from an administrative database of pharmacies-derived regional 
data regarding medication prescriptions in Campania region, Southern Italy, which has 
a population of about six million inhabitants. For this study, we used data collected in 
the years 2009-2011. The database contains all the information concerning outpatient 
drug prescriptions reimbursed by the National Health Service (NHS) and dispensed in 
pharmacies of the entire Campania region.  
The database also includes demographic information (i.e. age, gender). To protect the 
patients’ privacy, the patient code was encrypted into a unique alpha-numeric code. 
The reliability of this strategy as a way of producing epidemiological information has 
been previously documented [8]. The drugs are classified according to the Anatomical 
Therapeutic Chemical (ATC) classification system. 
The study was designed as a retrospective cohort study. Subjects 40 years of age or 
older were included if at least one prescription for any anti-osteoporotic drug had 
been filled in between July 1, 2009 and June 30, 2010. The date of first prescription 
was considered as the index date. Criteria for patients’ selection have been described 
in a previous paper [8]. Patients were followed from the index date until the 
discontinuation of anti-osteoporotic therapy or until the end of the observation period 
(June 30, 2011). For each patient, the following characteristics were assessed from the 
database at baseline: age, gender, co-prescription of calcium/vitamin D and switch. 
Patients were stratified into five cohorts based on dosing regimen treatment at the 
index date. Persistence was defined as the length of time in days from the date of the 
index prescription to the date of discontinuation therapy. Discontinuation was 
evaluated by using the gap method. A gap is a period during which no medication is 
available to the patient. A treatment period was considered discontinued if the gap 
between two prescriptions exceeded a period covered by drug prescribed > 30 days. 
Persistence was analyzed according to the type of dosing regimen. To avoid 
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underestimating true persistence, switching of medications was allowed when 
establishing persistence status for all treatments combined.  
 
Statistical Analysis 
Baseline characteristics of the study population were analyzed using descriptive 
statistics. Persistence esteems over time were derived using Kaplan–Meier survival 
analysis considering treatment discontinuation as failure event and comparing 
differences using Log-rank test (4 degrees of freedom). 
A multivariate Cox proportional hazard analysis was used to identify the association of 
dosing regimen and other variables with persistence with the initial medication. The 
patients who initiated with weekly bisphosphonates (BPs) regimen were used as the 
reference group. Statistical significance was defined at an α level of 0.05 with a hazard 
ratio higher than 1 indicating a relative increase in the risk of early discontinuation.  
All analyses were performed using SPSS software version 17.1 for Windows (SPSS Inc, 
Chicago, IL, USA 
Sensitivity analyses 
Sensitivity analyses were carried out for the measurement of persistence by extending 
the refill gap from the 30 days baseline analysis to 45 and 60 days. Sensitivity analyses 
were also performed using two alternative definitions of persistence, excluding or 
including patients who were switchers. 
4.2.3 Results 
In the study period, in Campania region, subjects with at least one prescription (of any 
drug) and aged over 40 years in our database were 1,690,192. Among these subjects, 
30,048 (1.78%) were incident users of anti-osteoporotic drugs: 1,731 (5.8%) males and 
28,317 (94.2%) females. The mean age (SD) of the cohort was 69.0 (10.0) years. 
Baseline characteristics of the study population are shown in table 1. Weekly BPs 
(51.1%), were the most commonly prescribed drugs, followed by strontium ranelate 
(SR) (30.2%), monthly BPs (17.5%), raloxifene (R) (0.7%) and daily BPs (0.4%). Co-
prescription with calcium and vitamin D was most common for monthly BPs (61%). On 
the other hand, patients starting with daily BPs and weekly BPs had fewer co-
prescriptions of calcium and vitamin D (35.8% and 39.8% respectively). In the overall 
study cohort, 1,532 (5.1%) were switchers. Switching rates were higher for patients 
taking daily BPs (21.6%) and lower for patients taking monthly BPs and weekly BPs 
(6.8% and 4.2% respectively).  
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Table 1. Baseline characteristics of the study population (N=30,048) 
  
Daily BP  
n (%) 
 
134 ( 0.4%) 
Weekly BP  
n (%) 
 
15,354 
(51.1%) 
Montly BP  
n (%) 
 
5,273 
(17.5%) 
Raloxifene    
n (%) 
 
198 (0.7%) 
S. Ranelate  
n (%) 
 
9,089 
(30.2%) 
Total 
Sex (female) n (%) 
117 
(87.31%) 
14,319 
(93.26%) 
5,000 
(94.82%) 
194 
(97.98%) 
8,687 
(95.58%) 
28,317 
(94.2%) 
Age (mean ±SD) 69.73±10.16 69.16±10.01 68.28±10.07 63.58±9.81 69.37±9.89 69.0±10.0 
Switcher n (%) 29 (21.64%) 639 (4.16%) 359 (6.81%) 8 (4.04%) 497 (5.47%) 1,532 (5.1%) 
 
Calcium – Vitamin D intake n 
(%) 48 (35.82%) 6,115 (39.83%) 
3,217 
(61.01%) 65 (32.83%) 
4,264 
(46.91%) 
13,709 
(46.2%) 
              
Table 2 summarizes cohort data at 90, 180, 270 and 365 days after initiation of 
treatment. In the overall population, 13.4% of subjects were still on therapy after one 
year. Persistence was higher when the refill gap period was increased: at 45 or 60 days 
persistence was 19.8% vs. 13.4% (≤30 days) and 23.8% vs. 13.4% (≤30 days), 
respectively, after 1 year. 
Table 2 . Persistence over time with oral osteoporosis treatments (switching allowed). 
Time point Total cohort  (N =30,048) 
  Patients on therapy (%) 95% CI 
3 months 59.2 58.6 – 59.8 
6 months 34.8 34.2 – 35.4 
9 months 22.3 21.9 – 22.7 
1 year 13.4 13.0 – 13.8 
Table 3 shows that inclusion or exclusion of switchers had minimal influence on the 
observed persistence; the rates differ by < 3%, independently from any definition of 
refill gap duration. 
Table 3 . Sensitivity analysis on 1 year persistence with regard to prescription gap and treatment switch. 
Prescription refill gap  Total cohort  (N =30,048) 
 Switchers* defined as non-persistent, n (%) Switchers defined as persistent, n (%) 
30 days 3,667 (12.2%) 4,025 (13.4%) 
45 days 5,396 (18.0%) 5,960 (19.8%) 
60 days 6,455 (21.5%) 7,156 (23.8%) 
*Switching of oral dosing regimen 
Switching of individual drugs within the same regimen ( changers) was not considered as non-persistence 
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Kaplan-Meier analysis showed the details grouped by individual regimen (Figure 1). At 
12 months the percentage of patients that remained on treatment was, in decreasing 
order: 17.2% for monthly BPs; 14.7% for weekly BPs; 8.1% for R; 5.4% for SR; 5.2% for 
daily BPs . 
 
Figure 1. One year persistence (%) with antiosteoporotic drugs. 
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A multivariate Cox proportional hazard analysis was estimated to identify variables 
that were significantly associated with non-persistence. The final estimated model is 
presented in table 4. Patients receiving daily BPs regimen and SR were at a higher risk 
of early discontinuation (HR 1.98 and 1.6, respectively) compared to patients in 
treatment with weekly BPs regimen. Moreover, patients treated with monthly BPs 
regimen had a lower risk of early discontinuation (HR 0.9) compared to patients in 
treatment with weekly BPs regimen. In our cohort, male gender was associated with a 
11% higher risk of discontinuation compared to female gender (HR 0.89). Patients who 
started treatment with a co-prescription with calcium and vitamin D had a lower risk of 
early discontinuation (HR 0.72).  
Table 4 . Determinants of non-persistence (multivariate Cox hazard model)  
Covariates HR p value      95%  CI 
Sex     
   Female 0.890 <0.001 0.844 0.937 
Dosing regimen     
     Daily BPs dosing regimen 1.983 <0.001 1.626 2.420 
     Montly dosing regimen 0.929 <0.001 0.896 0.963 
     Strontium Ranelate 1.614 <0.001 1.568 1.660 
     Raloxifene 1.289 0.001 1.110 1.497 
Calcium – Vitamin D intake      
     yes 0.717 <0.001 0.699 0.736 
 
4.2.4 Discussion 
Campania is a region of Southern Italy which has a total population of 5,834,056 [10], 
of which 1,690,192 (29%) are those aged over 40 years who are taking at least one 
drug, according to drug prescription database that includes all outpatient drug 
prescriptions reimbursed by the National Health Service (NHS),  and 1.78% of these are 
taking an anti-osteoporotic drug. In this cohort of patients, our data showed that the 
persistence to osteoporosis therapy is significantly worse than that reported in 
literature [11], but similar to a previous paper that considered a smaller population of 
the same region (not including population referring to the first Local Health District of 
Naples ASLNA1) in the year 2009 [8]. Although anti-osteoporotic drugs demonstrated 
to be effective, in clinical practice, anti-fracture effectiveness is significantly reduced 
by the high rate of discontinuation [12]. Siris et al. emphasized the importance of good 
treatment compliance and persistence with osteoporosis therapies in order to achieve 
a significant therapeutic benefit in terms of reduced rates of fragility fractures [13]. 
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Gallagher et al., analysing the United Kingdom General Practice Research Database, 
reported that only 41.7% of patients were still on treatment at one year, resulting in a 
reduction of hip fractures rate (-22%) [14]. In particular, in our cohort, only 34.8% and 
13.4% of the patients continued anti-osteoporotic treatment at 6 months and at one 
year respectively, after initiation of therapy, and this being a demonstration of a 
doubling of discontinuation rates compared to previous studies [12]. The most 
important risk factors of the lack of persistence to treatment seem to be the type of 
drug and the dose regimen. In 2007, a meta-analysis suggested that both compliance 
and persistence to drug therapy for osteoporosis were enhanced with weekly dosing 
compared with daily dosing regimen [15]. In our study, we reported a lower 
persistence rate in subjects treated with daily BPs or SR (5% in 1 year) than in subjects 
treated with monthly BPs (21.6%), that showed, in our cohort, the best persistence at 
1 year. The most common circumstances when patients and/or physicians consider 
changing medication are side effects and safety concerns, uncomfortable dosing, 
perception of ineffectiveness, and cost of drugs [9]. In our study, switching rates were 
higher for patients taking daily BPs or SR and lower for patients taking weekly BPs, 
highlighting the prominent role of side effects and inconvenient dosing regimens. In 
our cohort, male gender was associated with a higher risk of discontinuation compared 
to female gender (HR 0.89), that is much less than that reported in a previous study in 
Italian hip fracture patients [16]. Although there is little persistence with calcium and 
vitamin D supplementation alone, when it is combined with other anti-osteoporotic 
drugs, it positively influences the persistence rate [17]. Our study confirms that 
patients who received a co-prescription with calcium and vitamin D had a lower risk of 
early discontinuation (HR 0.72). The limitation of our study is due to the use of 
administrative database, which does not allow us to analyze potential clinical factors 
that negatively affect the persistence rates, including side effects, no perceived 
benefits, misinformation given by the physician, and lack of motivation. Our findings 
suggest that the prescription of drugs with less frequent dosing regimen represents 
the keystone of the therapeutic strategy to obtain an optimal persistence to anti-
osteoporotic drugs. 
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4.3 Assessment and potential determinants of compliance and 
persistence to anti-osteoporosis therapy in Italy 
Abstract  
Objectives: To analyze  adherence to anti-osteoporosis drugs(AODs) and to assess the 
influence of patient-related and drug-related factors. Study Design: Observational, 
retrospective study. Methods: Data on prescriptions for AODs from 2007 through 2008 
were retrieved from the administrative databases of10 Italian local health units. Key 
measurements included  compliance and persistence at 1 year. Multivariate regression 
analyses were performed to estimate adjusted risk ratios for compliance less than 80% 
and adjusted hazard ratios for no persistence. Results:  Of 40,004 new patients (89.9% 
women, mean age 69.8 years), 84.0% were treated with bisphosphonates and 74.6% of 
administration regimens were weekly. Overall, 75.1% of patients had suboptimal levels 
of compliance and 84.7% were not persistent; almost one-third had only 1 
prescription.  In regression analyses, younger age, change of drug, and concomitant 
corticosteroid therapy were significantly associated to compliance and persistence in 
both genders. In women, weekly and monthly regimens reduced the risk for poor 
compliance (sex-adjusted relative risks 0.729 [0.697-0.762], 0.846 [0.817-0.876], 
respectively) and no persistence (sex-adjusted hazard ratios 0.591 [0.541-0.646], 0.508 
[0.461-0.560], respectively) compared with a daily regimen. Conclusions: In our study, 
75% of subjects had discontinuous treatment and inadequatedrug supply. Age and 
frequency of administration were strongly associated with adherence. Improvement is 
urgently needed, and occasional prescriptions represent the main target. 
4.3.1 Introduction 
Osteoporosis has become a clinical and public health concern because osteoporotic 
fractures are one of the most common causes of disability and reduced quality of life, 
and an important contributor to medical costs in many regions of the world [1]. 
Several medications are currently available for the prevention and treatment of 
osteoporosis [2]. However, the effectiveness observed in trials may not be applicable 
to daily practice, where 50% to 80% of patients discontinue bisphosphonate use in the 
first year of therapy [3,4]. Moreover, noncompliance with bisphosphonates has also 
been reported to be a frequent issue, with rates varying from 35% to 65% of 
medication possession ratio [4].  
The full benefits of medications for osteoporosis cannot be reached if compliance is 
low: poorly compliant patients have a greater risk of fractures than patients who 
adhere to their prescribed therapy [5], resulting in higher healthcare use and costs [6].   
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The aim of this study was to investigate compliance and persistence with 
antiosteoporosis drugs (AODs) in a sample of new users and to assess the influence of 
potential determinants.  
4.3.2 Methods 
Data Source 
Data used for this retrospective pharmacoepidemiological study were retrieved from 
the health service databases of the Local Health Units (LHUs) —provincial-level 
divisions 
of the Regional Health Authority—of Bergamo (Lombardy Region, Northern Italy), 
Avezzano-Sulmona, Chieti, Lanciano-Vasto, Teramo (Abruzzo Region, Southern Italy), 
Avellino, Benevento, Caserta, Napoli Nord, Salerno (Campania Region, Southern Italy), 
with a total population of about 5.5 million people, entirely covered by the National 
Health Service (NHS).  
Prescription data contain dispensed drug name (commercial and international 
common denomination), Anatomical Therapeutic Chemical (ATC) classification 
category, dose, number of packs, and date of dispensation. We used the demographic 
database to retrieve demographic  information about patient (gender and age). 
In compliance with Italian law on privacy, Health Authorities converted patient 
personal codes to anonymous codes.  
Data Selection 
AIFA, which is the Italian Medicines Agency and national authority responsible for drug 
regulation in Italy, has approved 3 bisphosphonates (alendronate, ibandronate, and 
risedronate) and 4 other drugs (raloxifene, teriparatide, strontium ranelate, and 
parathyroid hormone) for the treatment of osteoporosis. Oral bisphosphonates are 
available for daily (alendronate, risedronate), weekly (alendronate, risedronate), or 
monthly (ibandronate, risedronate) dosing. The Italian government grants 
reimbursement for AODs in cases of osteoporosis diagnosed by computerized bone 
mineralometry (T score less than –4, or less than –3 in high-risk patients), previous 
vertebral fractures, or chronic therapy with corticosteroids in subjects older than age 
50 years. 
Patients were included in this analysis if they received a prescription of AODs between 
January 1 and December 31, 2007. A retrospective analysis covering the period from 
January to December 2006 was performed to identify new users, excluding subjects 
who had been prescribed any osteoporosis treatment during the 12-month period 
prior to the index prescription. The first claim for an AOD during the study period was 
considered the patient’s index date. We also obtained information about any 
prescription of corticosteroidsduring the period of 2006 to 2008 . Each patient was 
followed up prospectively for 1 year. Subjects were classified into treatment groups 
based on the study drug first received.  
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Outcome measures 
To evaluate treatment compliance and persistence in our cohort, according to 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
definitions [7-9], the length time with drug available for each refilled prescription was 
calculated using specific Defined Daily Doses (DDDs) [10]. Switching  products was not 
considered an interruption. 
Compliance (adherence) was measured as medication possession ratio (MPR), 
calculated as the total number of days of drug supplied in the observation period 
divided by the total number of days in the observation period (365), calculated as a 
percentage. Optimal compliance with therapy was defined by MPR of at least 80%.  
Persistence was quantified by the number of days covered by drug from initiation to 
discontinuation of therapy . Discontinuation occurred when the period between the 
end of the coverage of a prescription and the date of the refill was longer than the 
permissible gap of 30 days [11, 12].  Patients with at least 1 discontinuation episode 
were considered nonpersistent, even if they subsequently restarted treatment. A 
sensitivity analysis was performed in order to determine the influence of the duration 
of the permissible gap on the results. 
Statistical analysis 
MPR was described by mean values and by distribution of patients across MPR classes. 
Persistence rates were evaluated using Kaplan–Meier survival analysis. Heterogeneity 
tests across groups were undertaken using the unpaired student’s t test or a 1-way 
analysis of variance (ANOVA) for continuous variables, and χ2 test for categorical 
measures, as appropriate. The impact of some sociodemographic and clinical variables 
on MPR was estimated using multivariate. Poisson regression analysis (dependent 
variable: MPR <80%). As persistence can change over time, we use a Cox proportional 
hazards model (dependent variable: nonpersistence). Both regression analyses were 
adjusted for LHUs. All analyses were performed using SPSS 19.0 (SPSS Inc, an IBM 
Company , Chicago, Illinois). 
4.3.3 Results 
We identified 40,004 new users of AODs in 2007: 35,956 women (89.9%, mean age 
[standard deviation] 69.8 years [11.2]), 4048 men (mean age [SD] 69.6 years [13.9]). Of 
those, 1792 subjects were 50 years or older and on chronic corticosteroid therapy: 
1403 women (3.9%) and 389 men (9.6%). Characteristics of prescriptions are reported 
in Table 1. Alendronic acid was the most commonly prescribed drug (with or without 
colecalciferol, 45.8% women  and 53.2% men), followed by risedronic acid and 
strontium ranelate. Antiosteoporosis therapy was mainly administered weekly (97.2% 
of all prescriptions of only alendronic acid and 96.6% of all prescriptions of risedronic 
acid). Generics were used by 6.1% of both women and men. The switch to another 
drug was more frequent than the change of administration regimen (10.0% vs 6.3%).  
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Compliance is reported in Table 2. Although suboptimal in 75.1% of our total sample, 
compliance was better for women. 
 
More than 70% of subjects had already interrupted their treatment after 6 months 
(Figure). 
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At 1 year, persistent women and men were 15.9% and 10.1%, respectively. In these 
groups, mean compliance was about 100%. Of the nonpersistent population, females 
(87.7%) and males (92.8%) had suboptimal compliance; about one-third of 
nonpersistent women and half of  nonpersistent men had only 1 prescription in the 
study period (Table 3). Excluding these subjects, mean MPR levels were 64.3% in 
women and 58.1% in men. On the other hand, 46.2% and 29.2% of nonpersistent 
women and men, respectively, showed at least 1 prescription after the interruption 
(Table 3). The sensitivity analysis with a permissible gap of 60 days showed a 
persistence rate of 40.5%. 
 
Table 4 reports adjusted risk ratios for suboptimal compliance and shows that female 
subjects younger than 50 years and those 75 years or older were at higher risk of 
suboptimal compliance, while weekly or monthly administrations (women only), 
change of drug or of frequency of administration, and concomitant use of 
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corticosteroids were associated with a lower risk of noncompliance. Similar patterns 
can be seen in the adjusted hazard ratios for nonpersistence (Table 4). 
 
4.3.4 Discussion 
Osteoporotic fractures represent one of the most common causes of disability and are 
associated with enormous healthcare expenditure. Although several specific therapies 
are available, accumulating evidence suggests that these agents are underused in 
clinical practice [13]. Moreover, even in subjects undergoing therapy, the management 
of osteoporosis is  difficult because of poor compliance [5].  
Several studies showed that a significant proportion of female patients stopped their 
treatment within 6 months of initiation and more than half did so within 1 year  [4, 14]. 
In addition, observational studies, although showing wide variations, reported high 
rates of suboptimal adherence  [15, 18]. McCombs and colleagues reported a mean 
MPR of 68%, 1-year persistence rates of 24.2%, and mean lengths of persistence of 170 
days for bisphosphonates[19]. Downey and colleagues observed a 12-month 
prevalence of optimally compliant patients (MPR ≥80%) of less than 60%, with 
persistence rates of 20% [15].  
 Results of previous studies are not always directly comparable to ours due to a 
number of methodological differences such as the population selected, the definition 
of compliance and persistence, the duration of follow-up, analytical techniques used, 
and differences in settings (populations, practices, and healthcare systems)[20]. 
Nonetheless, our findings are consistent with data from other studies, highlighting the 
widespread problem of poor adherence to antiosteoporosis therapy. In our study 
mean MPR was less than 50%; the optimal compliance rate was 25%;  and proportion 
of persistent subjects was about 15%. These values are mainly the consequence of the 
high percentage of subjects with only the first prescriptions (almost 1 out of  3 patients 
with only 1  prescription in the observed year), a finding particularly relevant in the 
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male cohort (48%) and in younger subjects (53% among subjects <50 years).Evaluation 
of the adherence in patients with at least 2 prescriptions showed significantly higher 
values (mean MPR was 64.3% in women and 58.1% in men). 
As AODs are characterized by side effects (gastrointestinal, musculoskeletal, 
neurological) and transient symptoms that adversely affect the quality of life of the 
patient, the properties of these drugs may be responsible, at least in part, for the 
observed large proportion of users with only 1 prescription[21].  
The simple distinction between compliant subjects and those exhibiting suboptimal 
compliance, as well as that between persistent and nonpersistent subjects, provides 
only a rough description of patient attitude toward drug use, and is strongly influenced 
by the choice of analysis parameters (an analysis performed with a permissible gap of 
60 days showed a persistence rate of 40.5%). In fact, among nonpersistent subjects, 
12% had the medication available for more than 80% of the time, thus becoming part 
of the compliant group despite the presence of occasional therapeutic gaps. Therefore, 
the proportion of subjects with a discontinuous treatment and insufficient drug supply 
during 1 year decreased to 75% of the total cohort. These are the patients who may 
derive a lower-than-expected benefit from therapy. 
Indeed, it should be noted that non-persistence, as defined in this and other studies, is 
not necessarily equivalent to permanent treatment discontinuation, as patients may 
lapse and then resume treatment after a ‘drug holiday’ of variable duration. Actually, 
most publications that have examined persistence to osteoporosis pharmacotherapy 
have considered only the initial treatment episode. However, an underreported finding 
is that many patients who discontinue pharmacotherapy return to treatment after a 
variable gap, a percentage ranging between 30% and  50% of nonpersistent subjects  
[22, 23].   
In our study , 46% of nonpersistent women and 29% of nonpersistent men showed at 
least 1 prescription after the first gap. It is possible that these drug-free intervals could 
have been avoided through closer monitoring of these subjects by their physician. 
Previous studies were all conducted using female cohorts, and thus compliance and 
persistence data in men are scant. In a retrospective chart-review study of male 
veterans, Hansen and colleagues observed optimal compliance in 59% of patients[24]. 
Our study adds data showing that compliance and persistence rates  in men were 
lower than those estimated in women, mainly due to a greater proportion of subjects 
with only 1 prescription. In men, as reported in the literature, osteoporosis is a 
prevalent problem that is under-recognized and undertreated, and  morbidity and 
mortality following a fracture are also greater than they are for women  [25].  From 
this perspective, the observed low levels of adherence have even more clinically 
relevant implications, requiring more attention by physicians, especially in this 
population. 
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A few studies have investigated factors influencing nonadherence, identifying side 
effects, age, and therapeutic regimen as main determinants [11, 26- 29].  
In our regression analyses, age was a major determinant of poor adherence and non-
persistence, as both younger  age and older age increased risk, probably due to a 
reduced perception of adverse outcome from  osteoporosis  [30, 31] (which has low 
prevalence in people under age 50 years) and to the increased comorbidity and 
concomitant treatments at older ages (which may lead practitioners and patients to 
favour other therapies) [31, 32].  
A major perceived problem with oral bisphosphonates is the inconvenience of the 
regimen, and the association between complex drug regimens and compliance is well 
established [33]. Several studies showed that less frequent dosing regimens 
significantly improved levels of both compliance and persistence [34- 37]. This was 
confirmed in our female sample, supporting a great possibility of improvement from 
new formulations with delayed administration frequency.  
In our analyses, the presence of a therapy change has been shown to reduce the risk of 
non-adherence and non-persistence. This evidence may suggest the switch as an 
indicator of further attention by the physician (to counteract the onset of adverse 
effects or to meet the patient’s needs), but we should consider that switching to 
another brand may result in the accumulation of  drug units that are not used, which 
can lead to skewed levels of compliance. 
Data about patients who were prescribed bisphosphonates because of chronic 
corticosteroid therapy are scarce. A study by Curtis and colleagues evaluated 
persistence and compliance to bisphosphonates at 2 years among corticosteroid users 
and reported a mean MPR of 73% [38].  In our study, compliance levels within 
corticosteroid therapy were poor (mean MPR 56.4%), although higher than those of 
other patients (mean MPR 46.1%) and in regression analyses,  the use of 
corticosteroids significantly reduced risk of suboptimal compliance and of non-
persistence. It is likely that these patients are more aware of the risk of fractures and 
the importance of anti-osteoporosis therapy. 
The results of our study should be considered within the context of the study’s 
limitations, mainly related to the use of administrative registry as a data source. 
Although this database allows access to information on a large number of patients 
gathered in real-world conditions and repeated dispensing over regular intervals is a 
good proxy for actual compliance and persistence to treatment, pharmacy claims do 
not guarantee the real consumption of medications, nor do they reflect the actual 
timing or manner of use. In addition, the administrative database does not capture 
drugs taken during hospitalization and use of over-the-counter calcium and 
supplements including vitamin D, so we did not cover all anti-osteoporosis 
interventions. Moreover, data on many important clinical variables that may influence 
compliance and persistence are not available.  
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On the other hand, the absence of exclusion criteria specific for age, pathology , or 
concomitant treatment allowed us to evaluate the AOD utilization profile of an 
unselected population in the general practice setting. The enrollment of both gender 
into the study provided information about prescriptive patterns and adherence and 
persistence to therapy also in the male population. In addiction, we extended our 
observation to all medications recommended for osteoporosis treatment by Italian 
guidelines. 
Overall, our data underscore the urgent need to improve the use of antiosteoporosis 
drugs, and suggest some priorities for intervention to improve compliance and 
persistence. First, both patients and doctors should be more aware that, after the 
decision to start a pharmacologic therapy, this cannot be interrupted; and that a 
scheduled, close follow-up is crucial, at least during the initial months of therapy, to 
reduce drop-out rate after the first prescription. Second, indications to minimize side 
effects should be offered to the patients whenever these drugs are prescribed. The 
risk/benefit ratio for younger and older patients should also be expressed. Finally, 
weekly or monthly regimens should be the preferential choice. The results of such 
improvement strategies could be easily monitored using the administrative databases, 
as showed by the current study. 
4.3.5 Conclusions      
 This study confirms that compliance and persistence to antiosteoporosis drugs is 
suboptimal in everyday practice, with short periods of persistence and lengthy gaps in 
therapy, and with 75% of treated patients probably getting no benefit or only partial 
benefit from therapy. To address these issues, a strategy to detect first prescriptions 
without any refill should be implemented (such as automated alerts close to the end of 
drug availability after a prescription is filled), along with adequately planned follow-up 
to monitor treatment effectiveness and compliance, and selection of a drug regimen 
that can help patients be more compliant with therapy. This is an example of how 
administrative databases, when available, can be used to monitor drug use and to 
identify the areas in which improvement is needed to increase compliance and 
persistence to therapy. 
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4.4 Gender differences in medication taking behaviour: a case of 
osteoporosis 
Abstract  
The aim of this study is to perform gender specific analysis regarding the persistence to 
antiosteoporotic drugs by using administrative databases. Patients 60 years of age or 
older were included if at least one prescription for any antiosteoporotic drugs had 
been filled in between January 1, 2006 and December 31, 2006. The final cohort 
consisted of a total of 7,867 patients (87.2% women). The mean patient age for both 
genders at the index date was 74.5 years. The crude analysis of long-term gender 
persistence showed a significant difference between women and men users: the 
relative number of persistence patients after 1 year was 66.4% in men and 44.7% in 
women. The Kaplan Meier plots of time to persistence start to differ for men vs 
women approximately 60 days after treatment start. 
4.4.1 Introduction 
Osteporosis is mostly defined as the disease of women, because the prevalence and 
fracture rates are much higher in postmenopausal women than in older men. The 
prevalence of osteoporosis in Europe was estimated to be 27.6 million (22.1 million of 
women and 5.5 million of men) in 2010 [1]. 
In recent years, however, there has been increasing recognition that male osteoporosis 
also represents an important burden as a common cause of morbidity, mortality and 
health care expenditure [2-4]. Also, men are more likely than women to have 
osteoporosis that is undiagnosed and undertreated [5-6]. 
Moreover, bone fracture are important factors of high mortality and morbidity rates in 
osteoporotic patients. Lack of persistence is common among subjects using oral anti-
osteoporotic drugs, and leads to increased risk of fragility fracture [7-9]. The aim of this 
study is to perform gender specific analysis regarding the persistence to 
antiosteoporotic drugs. 
4.4.2 Materials and methods 
We conducted a retrospective cohort study using administrative data from four local 
health authorities in the Abruzzo Region (Central Italy), which comprise about 900,000 
inhabitants (68% of the overall regional population).  
Data sources  
The data used for this study were obtained from outpatient drug prescriptions, 
hospital discharges and ambulatory care records collected from January 1, 2005 to 
December 31, 2008 (study period). Briefly, outpatient drug prescriptions include all 
information about prescribed drugs reimbursed by the NHS (i.e. drug code, dose, 
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formulation, number of packages, date of prescription). Drugs are classified according 
to the Anatomical Therapeutic Chemical (ATC) classification system. Hospital 
discharges collect information on primary diagnosis, up to five secondary diagnoses, 
performed medical or surgical procedures,  date and ward of admission and discharge 
and in-hospital death. All diagnoses and procedures are codified according to the 
International Classification of Disease, 9th Revision (ICD-9-CM). This database includes 
the patients' personal identification number, procedure codes, date of prescription 
and costs.   
All data sources were matched by record-linkage analysis through a unique personal 
identification code that is encrypted to protect the patient's privacy and linked to the 
civil registry in order to collect demographic information (i.e. age, gender, date of 
death or emigration) of all residents covered by the NHS. The reliability of this strategy 
to produce clinical-epidemiological information has been previously documented. 
Because this automated system is anonymous, neither ethical committee approval nor 
informed consent was required for the present study. 
Study cohort 
The study was designed as a retrospective study cohort. Patients 60 years of age or 
older were included if at least one prescription for any antiosteoporotic drugs 
[Alendronate (ATCV:M05BA04); Alendronate + Vitamin D (ATC V M05BB03); 
Risedronate (ATC V M05BA07); Ibandronate (ATC V M05BA06); Raloxifene (ATC V 
G03XC01); Strontium Ranelate (ATC V M05BX03) and Teriparatide (ATC V H05AA02)] 
had been filled in between January 1, 2006 and December 31, 2006. The date of first 
prescription was considered as the index date. 
Three patient categories were excluded:  
• patients who had been prescribed antineoplastic drugs (L01) during follow-up;  
• patients with a medical claim for malignant bone cancer as a reason for 
hospitalization ( ICD-9: 170 e 198.5) or pathological fracture (ICD-9: 733.1); 
• patients who had not reached at least one year of follow-up and medical 
history. 
Patients were followed from the index date until the discontinuation of 
antiosteoporotic therapy or until the end of the observation period (31 December 
2008). For each patient, additional data elements available in the database include the 
following characteristics at the index date: age, gender, co-prescription of calcium/ 
Vitamin D, dosing regimen treatment, previous treatments, previous fractures, 
diagnostic tests and fractures. 
Persistence 
Persistence was defined as the length of time (in days) from the date of the index 
prescription to the date of discontinuation therapy. Discontinuation was evaluated by 
using the gap method. A gap is a period during which no medication is available to the 
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patient. A treatment period was considered discontinued if the gap between two 
prescriptions exceeded a period covered by drug prescribed > 30 days. Persistence was 
analyzed according to the type of dosing regimen. To avoid underestimating true 
persistence, switching of medications was allowed when establishing persistence 
status for all treatments combined. Switchers were considered discontinuers at the 
date of switch when persistence was estimated for the individual treatment types. 
Statistical Analysis 
Baseline characteristics of the study population were analyzed using descriptive 
statistics: quantitative variables were described by means and standard deviations 
while categorical variables were described by counts and percentages. Chi-square was 
used to examine the differences in proportion of persistence between males and 
females. 
Persistence estimates over time (discontinuation rates were assessed at 365 days) 
were derived using Kaplan–Meier survival analysis, stratifying for gender,  considering 
treatment discontinuation as failure event and comparing differences using Log-rank 
test ( 1 degree of freedom).  
All analyses were performed using SPSS software version 17.1 for Windows (SPSS Inc, 
Chicago, IL, USA). 
4.4.3 Results 
Cohort characteristics 
The final cohort consisted of a total of 7,867 patients, aged 60 or older, identified 
through records of filled prescriptions for an antiosteoporotic drug between January 1, 
2006 to  December 31, 2006 and satisfied the inclusion/exclusion criteria. Baseline 
characteristics of the study population according to gender are shown in Table 1. The 
majority of patients were women (87.2%), and 3.9% had a history of an osteoporotic 
fracture.  
Males and females were similar in mean age. The mean patient age for both genders 
at the index date was 74.5 years with 27.3% of the patients between 60 an 70 years of 
age, 46.1% of the patients between 70 and 80 years of age and 26.6% of patients ≥ 80 
years of age.  
The most common index prescription for the all population was weekly 
bisphosphonate (90.2% of the population), followed by daily bisphosphonate (4.4% of 
the population), strontium ranelate (2.5% of the population), raloxifene (1.7% of the 
population), monthly bisphosphonate (0.9% of the population) and teriparatide (0.4% 
of the population).  
There was no significant differences in previous treatment and prevalent fractures 
occurred one year before the index prescription histology between males and females 
(p = 0.665 and p = 0.760 respectively). Regarding concomitant medications, 
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approximately 19.4 % of the all patients used calcium and vitamin D besides 
osteoporosis medication (12.8% for males and 20.3% for females). 
About one-fifth of all subjects had experienced with spot therapy, but men were more 
likely than women to have a spot therapy experience (45.4% vs. 14.5%, p < 0.001). 
Approximately 6% of all included patients switched between the included medications 
outside dosing regimen but differences in switching patterns were analyzed between 
males and females: males had significantly more occurrences (18.9% vs 4.4%, p < 
0.001). 
Table 1. Baseline characteristics of the study population (N= 7,862) 
  
Male n (%)                         
1,009 (12.8) 
Female n (%)                      
6,858 (87.2)  
Total n (%)          
7,867 p value 
Age (mean ±SD) 74.6 ± 7.7 74.5 ± 7.7 74.5 ± 7.7  
Age groups        0,57 
     60-69 years 268  (26.6) 1,877  (27.4) 2,145 (27.3)  
     70-79 years 474  (47.0) 3,156  (46.0) 3,630 (46,1)  
     ≥ 80 years 267 (26.5) 1,825 (26.6) 2,092 (26.6)  
Initial druga       < .0001 
     Daily bisphosphonate 116  (11.5) 229  (3.3) 345  (4.4)  
     Weekly bisphosphonate 871  (86.3) 6,223  (90.7) 7,094  (90.2)  
     Montly bisphosphonate <0.1  (<0.1) 67  (1.0) 67  (0.9)  
     Raloxifene 7  (0-7) 123  (1.8) 130  (1.7)  
     Strontium ranelate 15  (1.5) 184  (2.7) 199  (2.5)  
     Teriparatide <0.1  (<0.1) 32  (0.5) 32  (0.4)  
Previous treatment  723  (71.7) 4,959  (72.3) 5,682 (72.2) 0,46 
Prevalent fracturesb 38  (3.8) 272  (4.0) 310 (3.9) 0,53 
Calcium - VitD intake  129  (12.8) 1,394  (20.3) 1,523  (19.4) < .0001 
Spot therapy 458  (45.4) 997  (14.5) 1,455  (18.5) < .0001 
Switcher 191  (18.9) 305  (4.4) 496  (6.3) < .0001 
Previous comorbidity       0.006 
     None 222  (22.0) 1,864  (27.2) 2,086  (26.5)  
     1 397  (39.3) 2,586  (37.7) 2,983  (37.9)  
     2 261  (25.9) 1,613  (23.5) 1,874  (23.8)  
     ≥ 3 129  (12.8) 795  (11.6) 924  (11.7)  
Test 707  (70.1) 5,395  (78.7) 6,102  (77.6) < .0001 
Fracture 40  (4.0) 366  (5.3) 406  (5.2) 0.066 
a Initial dosing regimen is calculated by each patient irrespective of switching   
 
b 1 year before the index prescription     
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Persistence 
The estimated Kaplan–Meier life table, with cumulative persistence rates (prescription 
refill gap ≤ 30 days) for the total population and gender-specific rates, are presented in 
Table 2. For the full cohort, persistence was 47.5 % (95 % CI, 46.3–48.7 %) after 1 year. 
Median time on treatment (time at which cumulative persistence rate is equal to 50 %) 
was 250 days.  
Table 2. Persistence over time with oral osteoporosis treatments (switching allowed) 
  
Time 
point Total cohort  (N = 7,867)   Women  (N = 6,858)   Men  (N = 1,009)   
  
Patients on therapy 
(%) 95% CI    
Patients on therapy 
(%) 95% CI    
Patients on therapy 
(%) 95% CI 
3 months 67.8 66.8-68.8   66.5 65.3-67.7   76.5 73.9-79.0 
6 months 54.8 53.6-56.0   52.6 51.4-53.8   69.8 67.0-72.5 
9 months 49.3 48.1-50.5   46.7 45.6-47.9   67.1 64.1-70.0 
12 
months 47.5 
46.3 - 
48.7   44.7 
43.5 - 
45.9   66.4 
63.4 - 
69.2 
Kaplan–Meier plots of the gender-specific data are shown in Fig. 1. The crude analysis 
of long-term gender persistence showed a significant difference between women and 
men users (log-rank test, p < 0.001): the relative number of persistence patients after 1 
year was 66.4% in men and 44.7% in women. The Kaplan Meier plots of time to 
persistence start to differ for men vs women approximately 60 days after treatment 
start (Fig.1). 
 
Figure 1: 1 year Kaplan–Meier survival curves showing the differences in outcomes 
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4.5  Persistence to therapy and the associated risk of fractures with 
antiosteoporotic drugs 
Abstract  
The aim of this study was to investigate the determinants of non-persistence and 
impact of persistence on the risk of fractures by using administrative databases. The 
final cohort consisted of a total of 7,862 patients, aged >60 years, identified through 
records of filled prescriptions for an antiosteoporotic drug between January 1, 2006 to  
December 31, 2006. 
Kaplan – Meier analysis showed that 3,733 patients (47.5%) were persistent with 
antiosteoporotic drugs  after 1 year. An adjusted analysis showed that there is a big 
difference in persistence between women and men: women are more likely to be non-
persistent than men (HR:1.94). Switcher patients were more likely to be non-persistent 
(HR:1.22). Persistence with antiosteoporotic drugs is a significant predictor of incurring 
a fracture. In the logistic regression analysis adjusted for potential confounders  odds 
of fracture were significantly lower for persistent patients (OR:0.79). 
4.5.1 Introduction 
Osteoporosis is a chronic progressive disease characterized by low bone mass and 
deterioration of bone structure, leading to an increate risk of fractures. It is a major 
public health problem, affecting hundreds of millions of people worldwide [1-2].  
The primary aim of pharmaceutical therapy is to reduce the risk of osteoporotic 
fractures. However, long-term adherence to therapy is requie for optimal therapeutic 
benefit for patients with osteoporosis. Poor adherence is considered to be one primary 
reason for suboptimal clinical benefit [3-6]. Several studies have shown that adherence  
to treatment of osteoporosis is poor, resulting in suboptimal real-world treatment 
effectiveness [7-14].  
The aim of this study was to investigate the determinants of non-persistence and 
impact of persistence on the risk of fractures. 
4.5.2 Materials and Methods 
We conducted a retrospective cohort study using administrative data from four local 
health authorities in the Abruzzo Region (Central Italy), which comprise about 900,000 
inhabitants (68% of the overall regional population).  
Data sources  
The data used for this study were obtained from outpatient drug prescriptions, 
hospital discharges and ambulatory care records collected from January 1, 2005 to 
December 31, 2008 (study period). Briefly, outpatient drug prescriptions include all 
information about prescribed drugs reimbursed by the NHS (i.e. drug code, dose, 
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formulation, number of packages, date of prescription). Drugs are classified according 
to the Anatomical Therapeutic Chemical (ATC) classification system. Hospital 
discharges collect information on primary diagnosis, up to five secondary diagnoses, 
performed medical or surgical procedures,  date and ward of admission and discharge 
and in-hospital death. All diagnoses and procedures are codified according to the 
International Classification of Disease, 9th Revision (ICD-9-CM). This database includes 
the patients' personal identification number, procedure codes, date of prescription 
and costs.   
All data sources were matched by record-linkage analysis through a unique personal 
identification code that is encrypted to protect the patient's privacy and linked to the 
civil registry in order to collect demographic information (i.e. age, gender, date of 
death or emigration) of all residents covered by the NHS. The reliability of this strategy 
to produce clinical-epidemiological information has been previously documented. 
Because this automated system is anonymous, neither ethical committee approval nor 
informed consent was required for the present study. 
Study cohort 
The study was designed as a retrospective study cohort. Patients 60 years of age or 
older were included if at least one prescription for any antiosteoporotic drugs 
[Alendronate (ATCV:M05BA04); Alendronate + Vitamin D (ATC V M05BB03); 
Risedronate (ATC V M05BA07); Ibandronate (ATC V M05BA06); Raloxifene (ATC V 
G03XC01); Strontium Ranelate (ATC V M05BX03) and Teriparatide (ATC V H05AA02)] 
had been filled in between January 1, 2006 and December 31, 2006. The date of first 
prescription was considered as the index date. 
Three patient categories were excluded:  
- patients who had been prescribed antineoplastic drugs (L01) during follow-up;  
- patients with a medical claim for malignant bone cancer as a reason for 
hospitalization (ICD-9: 170 e 198.5) or pathological fracture (ICD-9: 733.1); 
- patients who had not reached at least one year of follow-up and medical 
history. 
Patients were followed from the index date until the discontinuation of 
antiosteoporotic therapy or until the end of the observation period (31 December 
2008).  
Covariates 
For each patient, additional data elements available in the database include the 
following characteristics at the index date: gender, age, dosing regimen, previous 
treatments, previous fractures, co-prescription of calcium/ Vitamin D, Spot therapy, 
Swither, Comorbidity, diagnostic tests and fractures.  
Comorbidity 
Information on patients comorbidity were adapted to Age Adjusted Charlson 
Comorbidity Index (ACCI) scores which were calculated for each patient by taking into 
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account all comorbidity conditions present at the index date with additional points 
added for age.  
Diagnostic tests 
Study patients were classified as exposed or not exposed to diagnostic tests related to 
the bone fracture on the basis of the presence or absence of at least one prescription 
during the study period. Diagnostic tests were classified into: 1st level laboratory tests- 
ERA (code: 90.82.5), CBC (code: 90.62.2), fractionated serum proteins ( code: 90.38.4), 
calcemia ( code: 90.11.4), phosporemia ( 90.24.5), total alkaline phosphatase ( code: 
90.23.5), creatininemia (code: 90.16.3); 2nd level laboratory tests- ionized calcium 
(code: 90.11.6), TSH (code: 90.42.1), PHT (code: 90.35.5), 25OH-VitD (code: 90.44.6), 
cortisol (code: 90.15.3), immunofixation (code:90.69.2), anti-gliadin, anti-endomysium, 
anti-transglutamise antibodies (code: 90.48.06, 90.49.5, 90.49.7, 90.52.2, 90.53.6), 
transaminase (code: 90.09.2, 90.04.5), urinary electrophoresis proteins (code:90.39.1), 
neoformation turnover (code: 90.24.1, 90.35.4, 90.37.7), resorption turnover (code: 
90.16.7, 90.28.2, 90.36.6); 1st level instrumental tests- back X-ray (code: 87.23), 
umbocacral X-ray (code: 87.24), spine X-ray (code: 87.29), densiometry (code: 88.99.2, 
88.99.3, 88.99.5); 2nd level instrumental tests – spine MRI (code: 88.93, 88.93.1), Spine 
CT scan (code: 88.38.1, 88.38.2).  
Fracture 
Study patients were classified as exposed or not exposed to bone fracture on the basis 
of the presence or absence of at least one hospitalization event with primary or 
secondary diagnosis of osteoporotic fracture during follow-up. Hospitalizations were 
selected based on discharge diagnosis, present on the National Hospitalization 
Database (SDO), of probable osteoporotic fracture according to the International 
Statistical Classification of Disease and Related Health Problems 9th Revision (ICD-9) 
during follow-up: ICD-9 codes 820.0 to 820.1 (femoral neck fractures), 820.2 to 820.3 
(per-trochanteric femoral fractures), 820.8,820.9, 821.1,821.2,821.3 (other femoral 
fractures), 812 (humeral fractures), 824 (ankle fractures), 813 (forearm/wrist fractures) 
823 (proximal tibia/fibula), 805, 806 (vertebral fractures) 807.0, 807.1 (rib), 808 
(pelvis). 
Outcome measures 
The primary outcome of this study was persistence at one year. Persistence was 
defined as the length of time (in days) from the date of the index prescription to the 
date of discontinuation therapy. Discontinuation was evaluated by using the gap 
method. A gap is a period during which no medication is available to the patient. For 
the analysis of persistence, a treatment period was considered discontinued if the refill 
gap between two prescriptions exceeded a period covered by drug prescribed > 30 
days. Persistence was analyzed according to the type of dosing regimen. To avoid 
underestimating true persistence, switching of medications was allowed when 
establishing persistence status for all treatments combined.  
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In order to investigate the impact of persistence with antiosteoporotic drugs on the 
risk of fractures, the secondary outcome of this study was hospitalized osteoporotic 
fractures based on ICD-9 codes related osteoporotic fracture.  
Statistical Analysis 
Demographic and clinical characteristics of the study population were examined using 
standard statistical methods: continuous variables were described by means and 
standard deviations while categorical variables were described by absolute and 
relative frequencies.  
Persistence esteems over time were derived using Kaplan–Meier survival analysis 
considering treatment discontinuation as failure event and comparing differences 
using Log-rank test (4 degrees of freedom).The determinants of non-persistence, that 
showed an association with a p ≤ 0.25 in the univariate Cox regression analysis, were 
also considered as covariates in the multivariable Cox regression.  
A logistic regression model was performed to assess the relationship between 
persistence with antiosteoporotic drugs and odds of fracture; univariate and 
multivariate models were performed; in the multivariate model were entered all 
potential confunders (gender, age group, previous fractures, persistence at one year 
and ACCI) that were significant at the p ≤ 0.25 in the univariate model.  
All analyses were performed using SPSS software version 17.1 for Windows (SPSS Inc, 
Chicago, IL, USA). 
Sensitivity analyses 
Sensitivity analyses were performed for the occurrence of fracture.We considered 
fractures that occurred in the first three months after the index date as previous 
fractures and did not consider recurrent fractures after the first one. 
Additional sensitivity analyses were carried out for the measurement of persistence by 
extending the refill gap from the 30 day baseline analysis to 45 and 60 days.  
4.5.3 Results 
Baseline characteristics and study cohort  
The final cohort consisted of a total of 7,862 patients, aged 60 or older, identified 
through records of filled prescriptions for an antiosteoporotic drug between January 1, 
2006 to  December 31, 2006 and satisfied the inclusion/exclusion criteria. Baseline 
characteristics of the study population are shown in Table 1. The majority of patients 
were women (87.2%). The mean patient age at the index date was 74.5 years with 
27.3% of the patients between 60 an 70 years of age, 46.1% of the patients between 
70 and 79 years of age and 26.6% of patients ≥ 80 years of age.  
The most common index prescription for the all population was weekly 
bisphosphonate (90.2% of the population), followed by daily bisphosphonate (4.4% of 
the population), strontium ranelate (2.5% of the population), raloxifene (1.7% of the 
population), monthly bisphosphonate (0.9% of the population) and teriparatide (0.4% 
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of the population). About 4.4% of patients had fractures that occurred before the 
index date. Regarding coprescription of calcium and Vitamine D approximately 19.4 % 
of the all patients used calcium and vitamin D besides osteoporosis medication. About 
one-fifth of all subjects had experienced with spot therapy and approximately 6% of all 
included patients switched between the included medications. Patients were 
dichotomized into three escalating ACCI groups: 0, 1-3 and ≥ 5. In total, Zero score (0) 
was found in 91.6%, Mild score (1-4) was  found in 1.3% and Severe score (≥ 5) in 7.1%. 
At last, 77.6% of patients was exposed to diagnostic tests related to the bone fracture. 
Table1. Baseline characteristics of the included patients (N = 7,862). 
Patients analysed (N = 7,862) 
  
Female Sex, n (%) 6,856 (87.2) 
Age (mean ±SD) 74.53 + 7.66 
Age groups n (%)   
    60-69 years 2,145 (27.3) 
    70-79 years 3,628 (46.1) 
    >80 years 2,089 (26.6) 
Dosing regimena   
     Daily bisphosphonates 7,090 (90.2) 
     Weekly bisphosphonates 345 (4.4) 
     Montly bisphosphonates 67 (0.9) 
     Raloxifene 130 (1.7) 
     Strontium ranelate 198 (2.5) 
     Teriparatide 32 (0.4) 
Previous treatment, n (%) 5,681 (72.3) 
Previous fractures, n (%) 342 (4.4) 
Co-prescription of Calcium/Vit D, n (%) 1,523 (19.4) 
Spot therapy, n (%)  1,452 (18.5) 
Switcher, n (%) 496 (6.3) 
ACCI, n (%)   
    Zero Score      [0] 7,200 (91.6) 
    Mild Score      [1-4] 100 (1.3) 
    Severe Score  [≥ 5] 562 (7.1) 
Tests, n (%) 6,102 (77.6) 
Fractures, n (%) 374 (4.8) 
a Initial dosing regimen is calculated by each patient irrespective of switching 
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Persistence 
Kaplan – Meier analysis showed that 3733 patients (47.5%) were persistent with 
antiosteoporotic drugs  after 1 year when prescription refill gap ≤ 30 days. Persistence 
was higher when the refill gap period was increased. Adopting 45 or 60 days as refill 
gap, Kaplan-Meier curves show persistence rates of 4,793 (61.0%) and 5,363 (68.2%) 
respectively after 1 year (Fig.1). 
 
Fig. 1. Overall persistence patients treated with osteoporosis drugs therapy. 
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Determinants of non-persistence to antiosteoporotic drugs 
Determinants of non-persistence are shown in Table 2. An adjusted analysis showed 
that there is a big difference in persistence between women and men: women are 
more likely to be non-persistent than men [HR, 1.94, (95% CI, 1.73-2.18)]. No 
significant difference was found between a weekly and a daily dosing regimen [HR, 
1.04, (95% CI, 0.89-1.21)]. Switcher patients were more likely to be non-persistent [HR, 
1.22, (95% CI, 1.07-1.39)]. No significant difference was found to ACCI groups. 
Table 2. Determinants of non-persistence of osteoporosis medications (N = 7,862).  
Characteristics  
365 days 
persistenc
e (%) 
Unadjusted HR (95% 
CI) 
p-
value 
Adjusted HR (95% 
CI) 
p-
value 
Gender           
    Male 66.5 Reference       
    Female 44.7 1.88 (1.68-2.10) 
< 
0.001 1.94 (1.73-2.18) 
< 
0.001 
Dosing regimen           
    Daily bisphosphonates 50.1 0.95 (0.82-1.11) 0.547 1.04 (0.89-1.21) 0.666 
    Weekly 
bisphosphonates 46.6 Reference       
    Montly 
bisphosphonates 58.2 0.74 (0.51-1.07) 0.108 0.99 (0.68-1.44) 0.985 
    Strontium Ranelate 63.1 0.64 (0.51-0.80) 
< 
0.001 0.72 (0.57-0.91) 0.007 
    Raloxifene 54.6 0.82 (0.63-1.06) 0.122 0.76 (0.59-0.99) 0.041 
    Teriparatide 59.4 0.68 (0.39-1.16) 0.158 0.61 (0.35-1.04) 0.071 
Switcher           
    No 47.5 Reference       
    Yes 47.2 1.02 (0.90-1.15) 0.812 1.22 (1.07-1.39) 0.002 
Previous treatment           
    No 61.9 Reference       
    Yes 42.0 1.71 (1.58-1.84) 
< 
0.001 1.68 (1.55-1.82) 
< 
0.001 
ACCI           
    Zero score    [0] 47.2 Reference       
    Mild score    [1-4] 44.0 1.08 (0.83-1.40) 0.560 1.12 (0.86-1.46) 0.395 
    Severe score [≥5] 51.2 0.90 (0.80-1.02) 0.106 0.96 (0.85-1.09) 0.534 
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Influence of persistence on fracture risk 
For the analysis of the impact of persistence and other factors on the risk of fracture, 
persistence with antiosteoporotic drugs is a significant predictor of incurring a 
fracture. In the logistic regression analysis adjusted for potential confounders  odds of 
fracture were significantly lower for persistent patients [OR, 0.79, (95% CI, 0.63-0.97)]. 
Older patients were more likely to incur a fracture than younger [70-79: OR, 1.52, (95% 
CI, 1.13-2.06); ≥ 80: OR, 2.49, (95% CI, 1.83-3.39)]. The odds of fracture were 
significantly higher for patients with previous fractures in comparison with those 
without previous fractures [OR, 1.70, (95% CI, 1.12-2.59)] (Table 3.). 
 
Table 3. Logistic regression model: impact of persistence and other factors on the risk fracture. 
Characteristics  Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value 
Gender         
    Male Reference       
    Female 1.31 (0.93-1.85) 0.119 1.28 (0.91-1.82) 0.159 
Age         
    60-69 Reference       
    70-79 1.54 (1.14 -2.06) 0.005 1.52 (1.13-2.06) 0.006 
    ≥80 2.56 (1.89 -3.45) < 0.001 2.49 (1.83-3.39) < 0.001 
Previous fractures         
    No Reference       
    Yes 1.71 (1.58-1.84) < 0.01 1.70 (1.12-2.59) 0.013 
Persistence         
    No Reference       
    Yes 0.78 (0.63-0.97) 0.022 0.79 (0.63-0.97) 0.026 
ACCI         
    Zero score    [0] Reference       
    Mild score    [1-4] 0.86 (0.32-2.36) 0.772 1.35 (0.49-3.78) 0.562 
    Severe score [≥5] 1.50 (1.06-2.12) 0.022 1.33 (0.94-1.90) 0.112 
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4.6 Cost analysis of osteoporosis in real word clinical practice 
Abstract 
The aim of this study is to analyze healthcare costs of osteoporosis and to build a 
economic model cost-effectiveness of pharmacological intervents based on real world 
data. The cost analysis was conducted taking each healthcare service into account, i.e. 
drug therapy, diagnostic tests and hospitalization admissions, during the study period. 
A hypothetical scenario based on the real-life available evidence was constructed.The 
mean level of adherence to populate the hypothetical scenario of “full adherence” was 
set at MPR > 80 % . 
The model built by adding a step value, constrained by a normal random variable, to 
the real-word adherence of each subject so that the subject shifted to the hypotetical 
scenario of full adherence, in order to quantify the clinical outcome (number of 
fractures) achievable in the hypotetical scenario. 
Cost-effectiveness of full adherence compared to real world adherence was expressed 
in terms of Incremental Cost effectiveness Ratio (ICER) and the number of fractures 
avoided was set as an effectiveness unit of measure. The mean annual healthcare cost 
per fracture avoided was € 247.44, of which medical treatments and diagnostic tests 
accounted for € 103.60 (41.9%) and € 143.84 (58.1%), respectively. The mean annual 
helathcare cost per fractured patient was € 1,044.85, of which medical treatments, 
diagnostic tests and hospitalizations for osteoporotic fracture accounted for € 88.73 
(8.5%), € 169.48 (16.2%) and € 786.65 (75.3%), respectively.  
4.6.1 Introduction 
Adherence to medications is poor and suboptimal in many chronic diseases. 
Nonadherence can reduce treatment effectiveness and can negatively affect 
healthcare costs and thus the treatments’ cost-effectiveness. 
Adherence in the setting of osteoporosis has been shown to be just as problematic, if 
not worse, than that in other chronic diseases [1-4].  
Economic evaluations based on modelling are commonly used to compare alternative 
treatment strategies in osteoporosis, to support decision-makers and to inform 
treatment guidelines [5-7]. 
Decision models can be used to forecast the results of clinical trials which usually 
provide a short follow up. These usually represent the bases for economic evaluations. 
Moreover, if adequately designed, decision making models allow taking uncertainty 
around parameters into accont, and to account for the lack of compliance that can be 
observed in clinical practice.  
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When first and second order uncertainty are fully explored andreliable real world data 
are used to popultate the model, then generalizable results can be obtained and the 
information produced can be considered relevant even to different jurisdictions.  
Given this backdrop, the aim of this study is to analyze healthcare costs of 
osteoporosis though an economic model to compute the cost-effectiveness of 
pharmacological regimens based on real world data.  
4.6.2 Matherial and Methods 
Data source 
The data of the analysed subjects were drawn from the administrative databases of 
four Local Health Authorities in the Abruzzo Region (Central Italy), which comprise 
about 900,000 inhabitants (68% of the overall regional population). Database contain 
information about outpatient drug prescriptions, hospital discharges and ambulatory 
care records collected from January 1, 2005 to December 31, 2008 (study period). 
Briefly, outpatient drug prescriptions include all information about prescribed drugs 
reimbursed by the NHS (i.e. drug code, dose, formulation, number of packages, date of 
prescription, drugs cost). Hospital discharges collect information on primary diagnosis, 
up to five secondary diagnoses, performed medical or surgical procedures,  date and 
ward of admission and discharge and in-hospital death. All diagnoses and procedures 
are codified according to the International Classification of Disease, 9th Revision (ICD-
9-CM). This database includes the patients' personal identification number, procedure 
codes, date of prescription and costs.  All data sources were matched by record-linkage 
analysis through a unique personal identification code that is encrypted to protect the 
patient's privacy and linked to the civil registry in order to collect demographic 
information (i.e. age, gender, date of death or emigration) of all residents covered by 
the NHS. The reliability of this strategy to produce clinical-epidemiological information 
has been previously documented. Because this automated system is anonymous, 
neither ethical committee approval nor informed consent was required for the present 
study. 
Patient included 
Patients 60 years of age or older were included if at least one prescription for any 
antiosteoporotic drugs had been filled in between January 1, 2006 and December 31, 
2006. The date of first prescription was considered as the index date. 
Osteoporotic Fracture 
The patients included in the analysis were classified as exposed or not exposed to 
osteoporotic fracture on the basis of the presence or absence of at least one 
hospitalization event with primary or secondary diagnosis of osteoporotic fracture 
during the follow-up. Hospitalizations were selected based on discharge diagnosis, 
reported on the National Hospitalization Database (SDO), of probable osteoporotic 
fracture according to the International Statistical Classification of Disease and Related 
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Health Problems 9th Revision (ICD-9) during the follow-up. The following ICD-9 codes 
were considered relevant to the current analysis: 820.0 to 820.1 (femoral neck 
fractures), 820.2 to 820.3 (per-trochanteric femoral fractures), 820.8, 820.9, 
821.1,821.2, 821.3 (other femoral fractures), 812 (humeral fractures), 824 (ankle 
fractures), 813 (forearm/wrist fractures) 823 (proximal tibia/fibula), 805, 806 
(vertebral fractures) 807.0, 807.1 (rib), 808 (pelvis). 
Adherence to therapy  
For each group, exposed or not to osteoporotic fracture, compliance with 
antiosteoporotic drugs was calculated. Compliance was quantified by the Medication 
Possession Ratio (MPR), which has become a standard method of evaluating drug 
compliance and is defined as the number of prescribed therapy units (daily doses) 
divided by the number of assumed for prescription periods that extended beyond the 
end of the study period. Patients were considered compliant if their MPR was > 80%. 
This value is commonly used as a cutoff point when evaluating compliance. 
Healthcare costs and resources use 
The cost analysis was conducted taking into account each healthcare good or service - 
drug therapy, diagnostic tests and hospitalization admissions – consumed by the 
patient during the study period. Healthcare resources where quantified under the NHS 
perspective. More in detail:  
- drug cost has been calculated based on the amount of money the health 
system reimbursed to providers of care; 
- diagnostic test cost has been calculated basing on the national tariff for 
outpatient services: 
- hospitalization cost was obtained from National Hospitalization Database (SDO)  
The mean annual healthcare cost per patient in the follow-up was also calculated.  
Model Structure 
Data source was represented by the evidence emerging from the studies described 
above which showed poor adherence to antiosteoporotic drugs and the relationship 
between persistence with antiosteoporotic drugs and risk of fracture (OR 0.79) . 
Based on the real-life evidence available a hypothetical scenario was construcred. 
The average level of adherence to achieve the hypothetical scenario of “full 
adherence” was estimated at MPR > 80 % . 
The model was built by adding a step value, constrained by a normal random variable, 
to the real-word adherence of each subject so that the subject shifted to the 
hypotetical scenario of full adherence , in order to quantify the clinical outcome 
(number of fractures avoided) in the hypotetical scenario. 
Cost-effectiveness was expressed in terms of Incremental Cost effectiveness Ratio 
(ICER). This indicator is calculated as the ratio between the incremental costs and the 
incremental efficacy of the strategy under study compared to its alternative. The 
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indicator was calculated both in the hypothetical scenario of “full adherence” and at 
baseline (“real word adherence”) .  
The chosen measure of effectiveness was the number of fractures avoided. 
 
ICER =  Healthcare Costs “full adherence” – Healthcare Costs “real world adherence” 
N. fractures “full adherence” – N. fractures “real world adherence 
 
4.6.3 Results 
Overall, 7,862 patients were prevalent users of antiosteoporotic drugs: 7,456 patients 
(94.8%) was not exposed to osteoporotic fracture  and 406 patients (5.2%) was 
exposed to osteoporotic fracture during the follow-up (Figure 1). 
Adherence to therapy  
Based on the calculated Medication Possesion Ratio (MPR),  adherence to therapy with 
antiosteoporotic drugs  after 1 year was 34.7% in fractured patients and 34.4% in not 
fractured patients (Figure 1). 
 
Figure 1: Flow chart selection 
 
Cost of healthcare services 
The mean annual healthcare cost per patient not fractued was € 247.44, of which € 
103.60 (41.9%) was for drug treatments and € 143.84 (58.1%) for diagnostic tests.   
The mean cost of drug treatments increased from € 54.57 in non adherent patients 
(MPR<80) to € 197.09 in adherent patients, while the cost of diagnostic testing ranged 
from € 106.50 in non adherent patients to € 215.04 in adherent patients. 
Consequently, the mean annual healthcare cost per not fractured patient increased 
from € 161.08 in non adherent patients to € 412.13 in adherent patients. 
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The mean annual helathcare cost per fractured patient was € 1,044.85, of which € 
88.73 (8.5%) was for drug treatments, € 169.48 (16.2%) for diagnostic tests and € 
786.65 (75.3%) for hospitalizations for osteoporotic fracture. 
The mean cost of drug treatments increased from € 69.15 in non adherent patients 
(MPR<80) to € 125.52 in adherent patients, while the cost of diagnostic testing ranged 
from € 63.92 in adherent patients to € 225.64 in non adherent patients. Consequently, 
the mean annual healthcare cost per patient fractured increased from € 1,003.69 in 
adherent patients to € 1,066.75 in non adherent patients.In conclusion, costs for 
fractured patients resulted to be about four times greater than those of not fractured 
patients. 
 
Table 3 – Total healthcare costs in osteoporotic patients, exposed and not exposed to osteoporotic 
fracure  
  
Drug 
treatments 
Diagnostic 
 tests 
Hospitalisations 
for fracture Total 
Not fractured 
    Adherents (MPR >80%) 
    N. patients  2,565 2,565 2,565 2,565 
Mean cost (€) 197.09 215.04 0 412.13 
Total cost  (€) 505,539.97 551,575.61 0 1,057,115.58 
 
Non adherents (MPR <80%) 
    N. patients  4,891 4,891 4,891 4,891 
Mean cost (€) 54.57 106.50 0 161.08 
Total cost  (€) 266,921.55 520,904.80 0 787,826.35 
 
Total 
    N. patients  7,456 7,456 7,456 7,456 
Mean cost (€) 103.60 143.84 0 247.44 
Total cost  (€) 772,461.52 1,072,480.41 0 1,844,941.93 
Fractured 
    Adherents (MPR >80%) 
    N. patients 141 141 141 141 
Mean cost (€) 125.52 63.92 786.65 1,003.69 
Total cost  (€) 17,698.14 9,012.30 110,917.65 141,520.53 
 
Non adherents (MPR <80%) 
    N. patients 265 265 265 265 
Mean cost (€) 69.15 225.64 786.65 1,066.75 
Total cost  (€) 18,324.62 59,795.00 208,462.25 282,687.46 
 
Total 
    N. patients  406 406 406 406 
Mean cost (€) 88.73 169.48 786.65 1,044.85 
Total cost  (€) 36,022.76 68,807.30 319,379.90 424,207.99 
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Cost effectiveness analysis  
The economic model showing simulating the improved outcome of real world patients 
if they achieved full adherence, showed that the average cost of medical treatments in 
case of optimal adherence per patient/year would increase (from € 88.73 in Real word 
adherence to € 125.52 in full adherence).  
Before this rising costs per year of drug therapy, the clinical outcome , expressed in 
terms of number of fractures, would decreases by 65%. In this scenario, also the total 
yearly costs related hospitalizations would decrease (from € 319,379 in real word 
adherence to € 110,917 in full adherence) . 
The ICER , expressed in terms of cost/fracture avoided equals € 821 ( Figure 2). This 
value indicates the cost that the NHS should support each fracture avoided.  
 
Figure 2: Incremental Cost Effectiveness Ratio 
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General Discussion 
Health-related automated databases are crucial systems to evaluate cost-effectiveness 
of intervention in a real world scenario. They are an innovative tool to assess 
adherence in large population and to evaluate cost-effectiveness of enhancing 
medication adherence. 
Up to now very few studies have been carried out by using real world data to evaluate 
cost effectiveness of intervention. The research as described in this thesis therefore 
was conducted in a large unselected population reflecting the patients’ treatment in 
the real-life setting and focused on pharmacoeconomic evaluation of improve 
adherence to treatment. 
Main findings 
The results showed sub optimal level of persistence. Our findings showed a lower level 
of adherence to antiosteoporotic drugs, persistence to therapy at 1 year was only 
47.5%, than in other countries. [1]. This could be explained by the fact that 
interventions to improve adherence to treatment in chronic diseases have been 
running for a long time in those countries, while in Italy action to improve adherence 
are still at a pilot stage. Recently the Italian medicine agency (AIFA) proposed a 
National Adherence Implementation Plan converging Scientific, Political and Economic 
efforts to apply system actions with effective clinical/economic impact. 
The results showed that drug regimen is one of the strong predictors of non-
adherence. Patients receiving daily BP and Strontium Ranelate were at a higher risk of 
early discontinuation, HR: 1.98 and HR: 1.6 respectively, compared to patients in 
treatment with weekly BPs regimen. Moreover, patients treated with monthly BPs 
regimen had a lower risk of early discontinuation (HR: 0.9) compared to patients in 
treatment with weekly BPs regimen. This is in line with evidence reported in the WHO 
(need for action) complexity and duration of the treatment regimen. Gender 
influences adherence to therapy and this is an issue that could be taken in strong 
consideration in tailor intervention to improve adherence. The analysis of gender 
persistence after 1 year showed a significant difference between women and men, 
44.7% and 66.4% respectively. Another aspect is comorbidity this highlighted that an 
approach centered on comorbidity/multimorbidity, could be more pertinent, in 
particular when address health issues concerning older people. About health care costs 
the results showed  that the mean annual healthcare cost was € 247.44 per patient not 
fractued  and € 1,044.85 per fractured patient. At last, the ICER , expressed in terms of 
cost/fracture avoided equals € 821. This value indicates the cost that the NHS should 
support each fracture avoided.  
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Strengths and weakness 
The relevance of our study is strengthened by the size of our sample and the ability to 
draw information from a real-world setting. Indeed, it is well known that findings from 
randomized clinical trials (RCTs) are not always representative of clinical practice 
especially to evaluate compliance. Observational studies such as the present report 
allow to explore the health outcomes of patients in routine care outside the limits of 
an RCT. Nevertheless, we acknowledge that a number of potential limitations might 
have influenced our results. The presence of unrecognized confounders could lead to 
overestimate the magnitude of the association between exposure and outcome as 
compared with the results of RCTs. In particular, our findings may be subject to 
confounding by indication due to the lack of randomization. Our dataset does not 
include information about the duration and severity of osteoporosis, clinical 
information (i.e. smoking and BMI). However, we attempted to limit the influence on 
the study outcomes by adjusting for age, gender, ACCI, presence/absence of previous 
fracture, previous treatment. Despite this limitation our findings are in line with 
findings from other studies highlighted [1,2]. 
Needs to share data for cross-national comparison  
Little is known about cross-national comparison (CNC) on adherence to medication 
and factors associated with non-adherence. Drug utilization studies have applied 
different methods to various data types to describe adherence to medication. 
Comparison of results of these studies is difficult owing to differences in the methods 
applied, data sources used and population groups selected [3].  Combining and sharing 
data across different European settings applying a uniform method of assessment 
could be useful, in order to increase sample size, to perform long-term studies and to 
share common strategies at EU level.  
Future perspective for economic evaluation by using real world data 
This thesis has highlighted how important can be real-world data to build economic 
models. Classic approaches are based on results from clinic trials, which can be of little 
use in taking informed decisions while planning health policies, although they still 
represent the most validated and robust methodology. 
Conclusion 
This thesis demonstrated the potential of the use of existing data sources to evaluate 
appropriateness of drug use. Drugs cost money to buy, but if we use them in an 
appropriate way we can also save costs in other areas. In particular enhancing 
adherence to medication may lead to reductions in the number of patients requiring 
hospitalization. This research only explored cost effectiveness of improve adherence in 
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drug use for osteoporosis, but clearly many different pattern of drugs for chronic 
conditions could be assessed in a similar way. 
Future perspective 
The data highlight the need for additional research. Findings of the present study may 
be a basis for future studies aimed at implementing health policies and educational 
efforts to improve medication adherence. Identification of interventions providing 
prescribing guidance. Identification of tools to support the delivery of effective 
medication reviews with rationalization of prescribing needs and effective 
communication of outcomes to patients and all actors involved in providing care. 
Enhancement of pharmacist role [4]. Action Group A1 of the European Innovation 
Partnership on Active and Healthy Ageing will develop these interventions, focusing on 
pilot initiatives and activities, as well as collaborative work and synergies across 
European partners, in order to both reduce disability and increment active life 
expectancy by improving prescribing quality and adherence to drug treatment [5]. 
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Appendix A: List of Antiosteoporotic drugs 
List of antiosteoporotic drugs according to ATC classification (V level ATC codes) 
included in the studies. The list is based on drugs used in outpatient setting and 
reimbursed by NHS, available on the Italian market at the data of the study. 
 
ATC V 
Code 
Drug Package Quantity Administration/Regimen 
G03XC01 Raloxifene 
14 pill -60 mg 
28 pill – 60 mg 
Daily 
Daily 
H05AA02 Teriparatide 1 pen – 28 doses 20mcg/80 µl Daily 
M05BA04 Alendronate 
14 pill – 10 mg 
4 pill – 70 mg 
Daily 
Weekly 
M05BA06 Ibandronate 1 pill – 150 mg Monthly 
M05BA07 Risendronate 
28 pill – 5 mg 
4 pill – 35 mg 
2 pill – 75 mg 
Daily 
Weekly 
Monthly 
M05BB03 Alendronate+Vit D 4 pill – 70 mg Weekly 
M05BX 03 Stronzium Ranelate 28 bags – 2g Daily 
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Appendix B: Hospitalizations for osteoporotic fracture 
The ICD-9 is an acronym for “International Statistical Classification of Disease and 
Related Health Problems 9th Revision”. This ninth edition is a publication form the 
World Health Organization comprising a set of codes that are used worldwide to 
classify diseases and injuries. The following table shows the list of ICD-9 codes that 
identify patient with hospitalization for osteoporotic fracture. 
ICD-9 Codes Description 
805 Fracture of vertebral column without mention of spinal cord injury 
805.0x Cervical, closed 
805.1x Cervical, open 
805.2 Dorsal [thoracic], closed 
805.3 Dorsal [thoracic], open 
805.4 Lumbar, closed 
805.5 Lumbar, open 
805.6 Sacrum and coccyx, closed 
805.7 Sacrum and coccyx, open 
805.8 Unspecified, closed 
805.9 Unspecified, open 
806 Fracture of vertebral column with spinal cord injury 
807.0 Rib(s), closed 
807.1 Rib(s), open 
808 Fracture of pelvis 
812 Fracture of humerus 
812.0x Upper end, closed 
812.1x Upper end, open 
812.2x Shaft or unspecified part, closed 
812.3x Shaft or unspecified part, open 
812.4x Lower end, closed 
812.5x Lower end, open 
813 Fractures of radius and ulna 
813.0x Upper end, closed 
813.1x Upper end, open 
813.2x Shaft, closed 
813.3x Shaft, open 
813.4x Lower end, closed 
813.5x Lower end, open 
813.8x Unspecified part, closed 
813.9x Unspecified part, open 
820 Fracture of neck of femur 
820.0x Transcervical fracture, closed 
820.1x Transcervical fracture, open 
820.2x Pertrochanteric fracture, closed 
820.3  Pertrochanteric fracture, open 
820.8  Unspecified part of neck of femur, closed 
820.9 Unspecified part of neck of femur, open 
821  Fractures of other and unspecified parts of femur 
821.0x Shaft or unspecified part, closed 
821.1x Shaft or unspecified part, open 
821.2x Lower end, closed 
821.3x Lower end, open 
824x Fracture of ankle 
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Appendix C: Diagnostic tests 
Patients were classified as exposed or not exposed to diagnostic tests related to the 
osteoporotic fracture. Diagnostic test are classified into:  
- 1st and 2nd level Laboratory Tests;  
- 1st and 2nd level Instrumental Tests. 
Laboratory 
Test Level 
Test code Description 
   1st 
90.11.4 Calcemia 
90.16.3 Creatininemia 
90.23.5 Total alkaline phosphatase 
90.24.5 Phosphoremia 
90.38.4 Fractionated serum proteins 
90.62.2 CBC 
90.82.5 ERA 
    2nd 
 
90.04.5 
90.09.2 
Transaminase 
90.11.6 Ionized calcium 
90.15.3 Cortisol 
90.16.7 
90.28.2 
90.36.6 
Resorption turnover 
90.24.1 
90.35.4 
90.37.7 
Neoformation turnover 
90.35.5 PTH 
90.39.1 Urinary electrophoresis proteins 
90.42.1 TSH 
90.44.6 25OH-VitD 
90.48.06 
90.49.5 
90.49.7 
90.52.2 
90.53.6 
Anti-gliadin, anti-endomysium, anti-tranglutaminase 
antibodies 
90.69.2 Immunofixation 
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Instrumental 
Test Level 
Test code Description 
   1st 
87.23 Back X-ray 
87.24 Umbocacral X-ray 
87.29 Spine X-ray 
88.99.2 
88.99.3 
88.99.5 
Densitometry 
   2nd 
88.38.1 
88.38.2 
Spine CT scan 
88.93 
88.93.1 
Spine MRI 
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Appendix D: Charlson Comorbidity Index (CCI) 
The comorbidity index developed by Charlson et al. is a validated method of classifying 
comorbidity to predict short- and long-term mortality from medical records. It replaces 
direct measures of the severity of an illness, which require a prospective data 
collection. The Charlson index assigns weights for a number of major conditions 
present among secondary diagnoses. The index score is the total of assigned weights, 
and represent a measure of the burden of comorbid disease.  
This index is a weighted measure that incorporates 19 different medical categories and 
each weighted according to its potential to impact on mortality. Those with a relative 
risk below 1.5 were assigned a weight of 1; conditions with a risk of 1.5 to <2.5 a 
weight of 2; conditions with a risk of 2.5 to <3.5 a weight of 3; and metastatic tumors 
and AIDS were assigned a weight of 6. The final score was calculated for each patient 
by taking into account all comorbid conditions present when the index was applied.  
In the following table is reported the list of scored comorbidities with their relative 
weight in the scoring system and the ICD-9 codes. 
Comorbid condition ICD-9 codes Weight 
Ischemic heart disease 410, 410.1, 410.2, 410.3, 410.4, 410.5, 410.6, 410.7, 410.8, 410.9, 412 1 
Congestive heart failure 
398.91, 402.01, 402.11,402.91, 404.01, 404.03, 404.11, 404.13, 
404.91, 404.93, 425.4, 425.5, 425.7, 425.8, 425.9, 428.0, 428.1, 428.9 
1 
Peripheral vascular disease 
093.0, 437.3, 440.0, 440.1, 440.2, 440.3, 440.8, 440.9, 441.0, 441.1, 
441.2, 441.3, 441.4, 441.5, 441.6, 441.7, 441.9, 443.1, 443.8, 443.9, 
557.1, 557.9, V43.4 
1 
Cerebrovascular disease 
362.34, 430, 431, 432, 432.0, 432.1, 432.9, 433, 433.0, 433.1, 433.2, 
433.3, 433.8, 433.9, 434, 434.0, 434.1, 434.9, 435, 435.0, 435.1, 
435.2, 435.3, 435.8, 435.9, 436, 437, 437.0, 437.1, 437.2, 437.3, 
437.4, 437.5, 437.6, 437.7, 437.8, 437.9, 438, 438.0, 438.1, 438.2, 
438.3, 438.4, 438.5, 438.8, 438.9 
1 
Dementia 
290.0, 290.1, 290.2, 290.3, 290.4, 290.8, 290.9, 291.0, 291.1, 291.2, 
291.3, 291.4, 291.5, 291.8, 291.9, 294.1, 331.2 
1 
Chronic pulmonary disease 
416.8, 416.9, 490, 491, 491.0, 491.1, 491.2, 491.8, 491.9, 492.0, 
492.8, 493.0, 493.1, 493.2, 493.9, 494.0, 494.1, 495.0, 495.1, 495.2, 
495.3, 495.4, 495.5, 495.6, 495.7, 495.8, 495.9, 496, 500, 501, 502, 
503, 504, 505, 506.4, 508.1, 508.8 
1 
Rheumatologic disease 
446.5, 710.0, 710.1, 710.2, 710.3, 710.4, 714.0, 714.1, 714.2, 714.8, 
725 
1 
Peptic ulcer disease 
531.0, 531.1, 531.2, 531.3, 531.4, 531.5, 531.6, 531.7, 531.9, 532.0, 
532.1, 532.2, 532.3, 532.4, 532.5, 532.6, 532.7, 532.9, 533.0, 533.1, 
533.2, 533.3, 533.4, 533.5, 533.6, 533.7, 533.9, 534.0, 534.3, 534.4, 
534.5, 534.6, 534.7, 534.9 
1 
Mild liver disease 070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9, 570, 
571.0, 571.1, 571.2, 571.3, 571.4, 571.5, 571.6, 571.8, 571.9, 573.3, 
573.4, 573.8, 573.9, V42.7 
1 
Diabetes mild to moderate 250.0, 250.1, 250.2, 250.3, 250.8, 250.9 1 
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Comorbid condition ICD-9 codes Weight 
Diabetes with chronic 
complications 
250.4, 250.5, 250.6, 250.7 2 
Hemiplegia or paraplegia 
334.1, 342.0, 342.1, 342.8, 342.9, 343.0, 343.1, 343.2, 343.3, 343.4, 
343.8, 343.9, 344.0, 344.1, 344.2, 344.3, 344.4, 344.5, 344.6, 344.9 
2 
Renal disease 
403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 
404.93, 582.0, 582.1, 582.2, 582.4, 582.8, 582.9, 583.0, 583.1, 583.2, 
583.4, 583.6, 583.7, 585, 586, 588.0, V42.0, V45.1, V56.0, V56.1, 
V56.2, V56.3, V56.8 
2 
Any malignancy, including 
lymphoma and leukemia 
140.0, 140.1, 140.3, 140.4, 140.5, 140.6, 140.8, 140.9, 141.0, 141.1, 
141.2, 141.3, 141.4, 141.5, 141.6, 141.8, 141.9, 142.0, 142.1, 142.2, 
142.8, 142.9, 143.0, 143.1, 143.8, 143.9, 144.0, 144.1, 144.8, 144.9, 
145.0, 145.1, 145.2, 145.3, 145.4, 145.5, 145.6, 145.8, 145.9, 146.0, 
146.1, 146.2, 146.3, 146.4, 146.5, 146.6, 146.7, 146.8, 146.9, 147.0, 
147.1, 147.2, 147.3, 147.8, 147.9, 148.0, 148.1, 148.2, 148.3, 148.8, 
148.9, 149.0, 149.1, 149.8, 149.9, 150.0, 150.1, 150.2, 150.3, 150.4, 
150.5, 150.8, 150.9, 151.0, 151.1, 151.2, 151.3, 151.4, 151.5, 151.6, 
151.8, 151.9, 152.0, 152.1, 152.2, 152.3, 152.8, 152.9, 153.0, 153.1, 
153.2, 153.3, 153.5, 153.6, 153.7, 153.8, 153.9, 154.0, 154.1, 154.2, 
154.3, 154.8, 155.0, 155.1, 155.2, 156.0, 156.1, 156.2, 156.8, 156.9, 
157.0, 157.1, 157.2, 157.3, 157.4, 157.8, 157.9, 158.0, 158.8, 158.9, 
159.0, 159.1, 159.8, 159.9, 160.0, 160.1, 160.2, 160.3, 160.4, 160.5, 
160.8, 160.9, 161.0, 161.1, 161.2, 161.3, 161.8, 161.9, 162.0, 162.2, 
162.3, 162.4, 162.5, 162.8, 162.9, 163.0, 163.1, 163.8, 163.9, 164.0, 
164.1, 164.2, 164.3, 164.8, 164.9, 165.0, 165.8, 165.9, 170.0, 170.1, 
170.2, 170.3, 170.4, 170.5, 170.6, 170.8, 171.0, 171.2, 171.3, 171.4, 
171.5, 171.6, 171.7, 171.8, 171.9, 172.0, 172.1, 172.2, 172.3, 172.4, 
172.5, 172.6, 172.7, 172.8, 172.9, 174.0, 174.1, 174.2, 174.3, 174.4, 
174.5, 174.6, 174.8, 174.9, 175.0, 175.9, 176.0, 176.1, 176.2, 176.3, 
176.4, 176.5, 176.8, 176.9, 180.0, 180.1, 180.8, 180.9, 182.0, 182.1, 
182.8, 183.0, 183.2, 183.3, 183.4, 183.5, 183.8, 183.9, 184.0, 184.1, 
184.2, 184.3, 184.4, 184.8, 184.9, 186.0, 186.9, 187.1, 187.2, 187.3, 
187.4, 187.5, 187.6, 187.7, 187.8, 187.9, 188.0, 188.1, 188.2, 188.3, 
188.4, 188.5, 188.6, 188.7, 188.8, 188.9, 189.0, 189.1, 189.2, 189.3, 
189.4, 189.8, 189.9, 190.0, 190.1, 190.2, 190.3, 190.4, 190.5, 190.6, 
190.7, 190.8, 190.9, 191.0, 200.0, 200.1, 200.2, 200.8, 201.0, 201.1, 
201.2, 201.4, 201.5, 201.6, 201.7, 201.9, 202.0, 202.1, 202.2, 202.3, 
202.4, 202.5, 202.6, 202.8, 202.9, 203.0, 203.1, 204.0, 204.1, 204.2, 
204.8, 204.9, 205.0, 205.1, 205.2, 205.3, 205.8, 205.9, 206.0, 206.1, 
206.2, 206.8, 206.9, 207.0, 207.1, 207.2, 207.8, 208.0, 208.1, 208.2, 
208.8, 208.9, 238.6 
2 
Moderate or severe liver 
disease 
456.0, 456.1, 456.2, 572.2, 572.3, 572.4, 572.8 3 
Metastatic solid tumor 
196.0, 196.1, 196.2, 196.3, 196.5, 196.6, 196.8, 196.9, 197.0, 197.1, 
197.2, 197.3, 197.4, 197.5, 197.6, 197.7, 197.8, 198.0, 198.1, 198.2, 
198.3, 198.4, 198.5, 198.6, 198.7, 198.8, 199.0, 199.1 
6 
AIDS 0.42 6 
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Age also was determined to be a significant contributing factor for overall survival and 
was subsequently incorporated into the Charlson comorbidity score to create a single 
index accounting for both age and medical comorbidity, the Age-Adjusted Charlson 
Comorbidity Index (ACCI). This modification to the Charlson index included the age of 
patient as a correction variable of the final score. For each decade after 40 years, a 
point is added: 1 point for age group 41-50 years, 2 points for age group 51-60 years, 3 
points for 61-70 years and 4 points for 71 years or older.  
The table below shows the points added to the score according to the age group of 
belonging. 
 
Scoring Age: 
Age groups Points 
< 40 years 0 
41 – 50 years 1 
51 – 60 years 2 
61 – 70 years 3 
71 – 80 years 4 
 
The overall score represents the weighted summation of their medical conditions with 
a high score representing a higher medical comorbidity. Patients were dichotomized 
into three groups by ACCI score: low score (0-1), mild score (2-3), severe score (≥4). 
 
 
 
 
 
 
 
 
  
98 
 
Appendix E: Statistical Methods 
In many studies the variable of direct interest is the length of time that elapses before 
some event occurs. This event may be death, or death due to a particular disease, and 
for these reason the analysis of such data is often referred as survival analysis. 
Survival times are then data that measure follow-up time from a defined starting point 
to the occurrence of a given event, for example the time from the beginning to the end 
of a remission period or the time from the diagnosis of a disease to death or, as in this 
study, the time from treatment of antiosteoporotic drugs initiation (index date) to 
discontinuation of therapy. 
A survival time is described as censored when there is a follow-up time but the event 
has not yet occurred or is not known to have occurred. Then, such survival times are 
termed censored, to indicate that the period of observation was cut off before the 
event of interest occurred. 
Standard statistical techniques cannot usually be applied to survival data because the 
underlying distribution is rarely normal and the data are often ‘censored’.  
In analyzing survival data, two functions that are dependent on time are of particular 
interest:  
• the survival function S(t) that is defined as the probability of surviving at least 
to time t; 
• the hazard function h(t) that  is the conditional probability of dying at time t 
having survived to that time. 
The graph of S(t) against t is called the survival curve. 
Kaplan Meier Method 
The Kaplan-Meier method can be used to estimate the survival curve from the 
observed survival times without the assumption of an underlying probability 
distribution: from a set of observed survival times (including censored times) in a 
sample of individuals, it is possible to estimate the proportion of people who would 
survive a given length of time under the same circumstances. The Kaplan-Meier 
method allows a table and a graph to be produced; these are referred to as the life 
table and survival curve respectively. 
To determine the Kaplan–Meier estimate of a survival function, a series of time 
intervals is formed. Each of these intervals is constructed to be such that one observed 
death is contained in the interval, and the time of this death is taken to occur at the 
start of the interval. A plot of the Kaplan–Meier estimate of the survival function 
(Figure 1) is then a step function, in which the estimated survival probabilities are 
constant between adjacent death times and only decrease at each death.  
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Figure 1. Kaplan-Meier estimate of the survival function 
 
 
Figure 2. Survival curves for two different groups 
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An important part of survival analysis is to produce a plot of the survival curves for 
each group of interest (for example, persistent and non-persistent group). However, 
the comparison of the survival curves of groups (Figure 2) should be based on a formal 
non-parametric statistical test called the log-rank test and not upon visual impressions. 
The log-rank test is used to test the null hypothesis that there is no difference between 
the population survival curves (i.e. the probability of an event occurring at any time 
point is the same for each population). 
The log rank test is used to test whether there is a difference between the survival 
times of different groups but it cannot be used to explore (and adjust for) the effects 
of other explanatory variables to be taken into account. Adjustment for variables that 
are known to affect survival may improve the precision with which we can estimate 
the treatment effect.  
Cox’s proportional hazards model 
The Cox model is a well recognized statistical technique for analyzing survival data. It is 
based on a modeling approach to the analysis of survival data. The purpose of the 
model introduced by Cox is to simultaneously explore the effects of several variables 
on survival. It is also known as proportional hazards regression analysis. 
Cox’s proportional hazard model is analogous to a multiple regression model and 
enables the difference between survival times of particular groups of patients to be 
tested while allowing for other factors. In this model, the response (dependent) 
variable is the “hazard”. The hazard is the probability of dying (or experiencing the 
event in question) given that patients have survived up to a given point in time, or the 
risk for death at that moment. 
A Cox model must be fitted using an appropriate computer program (such as SAS, 
STATA or SPSS). The final model from a Cox regression analysis will yield an equation 
for the hazard as a function of several explanatory variables.  
Interpreting the Cox model involves examining the coefficients for each explanatory 
variable. A positive regression coefficient for an explanatory variable means that the 
hazard (risk of death) is higher, and thus the prognosis worse. Conversely, a negative 
regression coefficient implies a better prognosis for patients with higher values of that 
variable. The p-values indicate if the difference between different groups  is or not 
statistically significant and if the 95% confidence interval for the hazard ratio includes 
1, it suggests no difference in survival. 
Cox regression is considered a semi parametric procedure because the baseline hazard 
function, h0(t), (and the probability distribution of the survival times) does not have to 
be specified. Because the hazard function is not restricted to a specific form, the semi-
parametric model has considerable flexibility and is widely used. 
 
